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General introduction & Outline of the thesis
GEnERAl oVERVIEw of DuPuytREn’S DISEASE
Dupuytren’s disease (DD) is a chronic progressive fibroproliferative disease character-
ized by flexion contractures of the fingers, especially in the metacarpophalangeal (MP) 
and proximal interphalangeal (PIP) joints(1). In DD the formation of palmar nodules has 
classically been described as the first sign of the disease, which is the result of myofi-
broblast proliferation and extracellular matrix synthesis(2). Myofibroblasts are the cells 
responsible for the development of the disease(3). In the later stages of DD, nodules ma-
ture to form collagen rich, acellular, fibrotic cords, which lead to digital contractures(4).
Hand function may be compromised due to these digital contractures. Especially 
fine motoric skills and reaching for objects where a straight hand is necessary (such 
as grabbing things under a closet, wearing gloves and shaking hands) are difficult for 
patients with DD (5). Therefore, reported patient burden can be high(6).
Associated diseases and symptom signs of DD are Peyronie’s disease, Ledderhose 
disease and Garrod’s knuckle pads. Peyronie’s disease affects the tunica albuginea of 
the penis and leads to a curvature in erection. When the plantar fibromatosis is affected 
it is named Ledderhose disease, characterized by nodules under the feet in the plantar 
fascia that cause walking and weight bearing problems. Garrod’s knuckle pads are 
nodules at the dorsum of the PIP-joints(1).
HIStoRy
The first reports mentioning fixed finger contractures dated from the 12th and 13th 
century in Orkney and Iceland. However, the first real description of the disease is 
from Felix Plater from Basel in 1614 (Figure 1A). Also Sir Henry Cline (1808) and 
Ashley Cooper (1818) were earlier in describing a surgical treatment for DD than baron 
Guillaume Dupuytren.
A B
figure 1: (A) Felix Plater, (B) baron Guillaume Dupuytren (Wellcome Library, London; Iconographic 
Collections) 
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The reason the disease was named after Guillaume Dupuytren (Figure 1B) and not 
Felix Plater, Henry Cline or Ashley Cooper were the lectures Dupuytren gave in Hotel 
Dieu in Paris and his publication ‘permanent retraction of the fingers, produced by an 
affection of the palmar fascia’ in the Lancet in 1834(7-10).
EPIDEmIoloGy AnD RISK fActoRS
The disease is more prevalent in the Northern part of Europe. Males are more affected 
than females and it is more common in older patients(11-13). Prevalence rates have been 
reported ranging from 0.2% to 56% in varying age and population groups(14). This large 
range can be explained by the fact that many studies mention ‘incidence’ rates but in 
fact calculate ‘prevalence’ rates, making it difficult to compare studies and blurring our 
view on the demographic distribution of DD(14).
Family predisposition and genetic pathways are described for DD(15, 16). Other fac-
tors such as smoking, alcohol consumption, excessive vibrations, manual labor, hand 
trauma, diabetes and epilepsy have also been linked to DD(17-25). These risk factors have 
been questioned because many studies are of low methodological quality and may not 
be based on representative samples of the general population(13, 26). However, a larger 
en more representative prevalence study from the Netherlands did find a relation with 
hand injury in the past and excessive alcohol consumption(13).
clInIcAl VARIAtIon
The clinical presentation of hands with DD differs tremendously (Figure 2). Most com-
monly, the fourth and fifth digit of the hand are affected, but it can also be seen in the 
other digits and interdigital webspaces(27, 28).
One of the reasons of this clinical variation is the severity of the underlying biology 
of the disease, which is called Dupuytren’s diathesis(16). Bilateral hand involvement, 
ectopic disease, family members with DD and an early onset of the disease are factors 
that influence the Dupuytren diathesis(29). A more severe diathesis will result in higher 
recurrence rates and may lead to multiple surgeries during lifetime. One study even 
reports a formula for Dupuytren diathesis to predict the risk for recurrent disease:
 ²⁄³Z + 3.83 = 0.97X1 + 0.84X2 + 0.96X3 + 1.77X4 + 2.24X5 + 2.29X6
This approximates to D = a + b + c + d + e + f, in which D is the diathesis score, a = 
bilateral hand involvement (with = 1, without = 0), b the little finger surgery (with = 1, 
without = 0), c the early onset of the disease (with = 1, without = 0), d the plantar 
fibrosis (with = 2, without = 0), and e the knuckle pads (with = 2, without = 0). This 
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study showed a high risk of recurrence and extension when the diathesis score was 
greater than four and a low risk when the diathesis score was less than four(30).
The second reason for the clinical variation is the different kind of retention-ligaments 
(lateral digital sheath, superficial fibrofatty palmar and dorsal fascia and Grayson’s 
ligaments) that can become pathologic components of the Dupuytren cord(31). For 
example, the spiral cord can originate from five different kinds of fascial structures 
and can cause a spiral nerve. In addition, the central cord, with its origin from the 
pretendinous band and palmar superficial fibrofatty fascia with its insertion into the 
skin over the proximal phalanx, is the most common cause of combined MP-joint and 
figure 2: Clinical variations of Dupuytren’s disease.
A B C D E
figure 3: Anatomic differences of digital cords: (A) central cord; (B) lateral cord; (C) isolated digital cord; 
(D) retrovascular cord; (E) thumb pretendinous cord. (Drawings made by C.F. Wilbrink)
Chapter 1
16
PIP-joint contractures(31). Because of these variations, knowledge about the anatomy of 
the Dupuytren fibers is essential for successful treatment (Figure 3).
tREAtmEnt oPtIonS AnD tHEIR outcomES
Many treatment options are available in clinical practice, such as radiotherapy, col-
lagenase injection, needle aponeurotomy, limited fasciectomy and dermofasciectomy.
Radiotherapy is popular in Germany. Studies have shown that radiotherapy reduces 
progression of the early signs of the disease (nodules and palpable cords). Radiotherapy 
treatment normally includes two separate treatment sessions with an interval of six 
weeks of five daily fractions of 3.0 Gy each to a total dose of 30 Gy. Radiotherapy 
has been reported as effective for preventing disease progression; one study reported 
progression of the disease in 13 years in 10% of the patients(32). However, it is unclear 
if radiotherapy can be used to treat DD contractures(33-35).
Collagenase injections are gaining more popularity, since it is minimally invasive and 
no operation room (OR) is needed(36). Collagenase is injected at several points along the 
cord. The next day the cord can be broken(37). The main disadvantages of this technique 
are that only one finger can be treated at one time. Furthermore the injections itself are 
very expensive, however studies have shown that the overall costs are lower compared 
to limited fasciectomy(38). Relatively low major complication rates have been reported 
compared to surgical treatments; however, minor complications such as edema and 
hematomas are high(39, 40). Since this technique has only been used for a few years, 
follow-up data on large study populations are lacking(41).
Needle aponeurotomy (NA) has been introduced by sir Henry Cline and was already 
used by baron Guillame Dupuytren in the 18th century(8). In the beginning, the technique 
was performed as an open transection of the Dupuytren cord. Today, the cord is tran-
sected percutaneously(42, 43). This minimal invasive technique has low overall complica-
tion rates, but reported recurrence rates range from 50% up to 84.9% after 5 years(44-47).
Limited fasciectomy (LF) may be the most commonly used technique in clinical 
practice. When using this technique, a longitudinal or Brunner incision is made into the 
palm overlying the affected area and extended towards the finger. The pathologic fascia 
is removed and neurovascular bundles and the flexor tendon sheaths are identified and 
protected(1). The skin will be transposed by a Z-plasty or other technique to lengthen the 
scar, to prevent scar contractures(1, 31). While complication rates are higher compared 
to NA, recurrence rates are lower(46, 47). Time needed to return to daily activity is about 
4 weeks(48).
Hueston has proposed Dermofasciectomy(49, 50). In this technique the affected fascia 
and the skin are removed and a full thickness graft is used to close the wound. This 
technique is mainly used to treat patients with severe diathesis and recurrent cases. The 
17
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idea is that the skin grafts act as a local ‘fire-break’ to prevent recurrence. Recurrence 
under the skin graft has hardly been seen(51). However, the recurrence rate of dermo-
fasciectomy after mean follow-up of 13 years is reported to be up to 47% and other 
reported recurrence rates ranges from 0% to 60%(52-54). Dermofasciectomy compared 
with fasciectomy even show the same recurrence rates of 12% after 36 months(53). 
The question remains what kind of definitions were used to define recurrence, and if 
recurrence was seen under the graft or if it was an extension outside of the graft area.
REcuRREncE
Overall, the currently available treatment strategies only treat or alter the symptoms of 
the disease rather than treat the underlying pathology. Therefore recurrence will occur 
sooner or later. Reported recurrence rates vary between 0% and 100%(53-58). Several 
studies have identified factors that influence these rates, such as follow-up time and 
diathesis(16, 30, 59). Since the treatment type may also influence recurrence rates, these 
recurrence rates are also an important aspect for assessing the effectiveness of treat-
ment. However, a review by Becker and Davis concluded that the outcome of surgery is 
inconsistent and that this inconsistency may be related to the different definitions of the 
term „recurrence”(60). Subsequently, evaluating the effectiveness of treatment methods 
is therefore impossible.
nEw mInImAl InVASIVE SuRGIcAl tEcHnIquE
In an attempt to overcome high recurrence rates after minimally invasive needle fasci-
otomy, Roger K. Khouri from the Miami Hand Clinic proposed a new treatment strategy, 
in which extensive percutaneous aponeurotomy is combined with lipofilling.
The concept of the percutaneous aponeurotomy and lipofilling (PALF) is the disinte-
gration of the fibrous cord through an extensive percutaneous needle aponeurotomy 
technique, applying numerous superficial nicks along the cord. Following percutane-
ous release of the skin from the subcutaneous layer with a needle, the treated area is 
injected with autologous lipoaspirate to restore the subdermal fat deficiency and to act 
as a ‘fire break’ graft(61).
In this technique, lipofilling is added since DD is associated with subdermal fat 
deficiency and atrophy as the pathologic fibrosis displaces the fat(62). In addition, the 
lipoaspirate used in this treatment strategy contains stem cells, and there is increasing 
evidence stem cells may be used as a treatment strategy to treat fibrotic diseases(63, 64). 
Studies showed that adipose-derived stem cells inhibit proliferation of the contractile 
myofibroblasts and mediate these effects by soluble factors, influenced by cell con-
tact(65). Since myofibroblasts are the key cells leading to the development of fibrosis 
Chapter 1
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and flexion contractures in DD, inhibiting myofibroblasts using lipoaspirate containing 
adipose-derived stem cells may avoid or reduce the development of recurrent contrac-
tures(3).
19
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AImS of tHIS tHESIS
The main aim of this thesis is to evaluate the effectiveness of extensive percutaneous 
aponeurotomy and lipofilling (PALF). This was initially performed in a pilot study of a 
cohort of patients treated in Miami and Rotterdam, and subsequently in a multicenter 
randomized controlled trial.
One of the difficulties in describing outcome in the treatment of DD however, is 
which definition of recurrence of disease is best to be used. Especially since recurrent 
rates are inconsistently defined in literature. In order to define recurrence, we studied 
the effect of different definitions in literature on a single data set and developed a 
Delphi study to propose a uniform consensus definition.
Furthermore, an important assumption of the new PALF technique, but also an 
assumption in other minimal invasive techniques such as collagenase and needle 
aponeurotomy is the fact patients prefer minimal invasive techniques in order to have 
a faster recovery after treatment. This assumption, however, has never been studied 
in this population and it is unclear how patients evaluate convalescence following 
contracture correction, recurrence rate and complication rate. Therefore, we developed 
a discrete choice experiment (DCE) to determine preferences for different techniques 
for treatment of DD.
outlInE of tHIS tHESIS
1. To evaluate the effect of different definitions for recurrence of DD and to develop a 
new uniform definition. (Chapter 2 and Chapter 3)
2. To study the relative importance of characteristics of DD treatment and the trade-
offs patients are willing to make. (Chapter 4)
3. To study and describe the long-term results of the treatment of patients with severe 
diathesis following flap surgery for both hands and feet. (Chapter 5)
4. To analyze the outcome of the new PALF technique, retrospectively and pro-
spectively and to compare the outcome with the most commonly used surgical 
technique. (Chapter 6 and Chapter 7)
Chapter 1
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AbStRAct
Background: Recurrence rates are important in the evaluation of the effectiveness of 
treatment for Dupuytren’s disease (DD). In literature, recurrence rates vary between 0% 
and 100%. The definition of recurrence of DD after treatment is inconsistently used. 
The aim of this study is to review all definitions of recurrence after treatment of DD and 
to evaluate the impact of using these definitions on a single cohort of patient’s treatment 
for DD.
Methods: A literature search was performed in PubMed and Embase to identify studies. 
Titles and abstracts were analyzed to collect all articles that described recurrence rates 
or definitions of recurrence. Two independent reviewers selected relevant studies and 
extracted data. The different definitions of recurrence were applied on our dataset of 
66 patients.
Results: Of the 113 articles reporting recurrent rates of DD, 56 (49%) presented a defi-
nition of recurrence. We could categorize the definitions into three groups. By applying 
the different definition on our dataset of a randomized controlled trial the recurrence 
rates ranged from 2% to 86%.
Conclusions: In literature, different definitions of recurrence of DD are used and many 
authors failed to define recurrence. This study shows that the wide range of reported 
recurrence rates may largely be contributed by inconsistency in recurrence definitions. 
As a result, it is difficult or even impossible to compare recurrence rates between dif-
ferent treatments reported in the literature. The study indicates that consensus on a 
recurrence definition is needed.
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IntRoDuctIon
Although the evidence for effectiveness of treatments for Dupuytren’s disease (DD) 
is still scarce, different treatment options are available in clinical practice, such as 
fasciectomy, aponeurotomy, and, more recently, collagenase injections(1-3). However, 
since current treatments only remove or alter the symptoms of the disease rather than 
treat the underlying pathology, recurrences occur. In literature, reported recurrence 
rates vary between 0% and 100%(4-10). Several studies have identified factors that influ-
ence these rates, such as follow-up time and diathesis(11-12). Since treatment type may 
also influence recurrence rates, it is an important aspect for assessing the effectiveness 
of treatment.
In a recent review, Becker and Davis concluded that the outcome of surgery is 
inconsistent and that this inconsistency may be related to the different definitions of 
recurrence used(13). Therefore, the first aim of this study was to identify all definitions of 
recurrence after treatment of DD reported in literature. Subsequently, we performed an 
analysis by applying the different definitions to a cohort of patients treated for primary 
DD, evaluating the effect of different definitions on the recurrence rate of these patients.
mEtHoDS
literature Search
To identify relevant articles on the recurrence of DD, we searched for studies published 
from January 1985 up to April 2011 using PubMed and Embase. Keywords related to 
recurrent DD were included, such as ‘Dupuytren’, ‘reappear’, ‘recurrence’, ‘return’, 
‘predict’, ‘prognosis’, ‘residual’, ‘remain’, and ‘outcome’. The complete search strategy 
can be found in Table 1.
Inclusion criteria and study selection
The search strategy results from Embase and PubMed were combined and duplicates 
were discarded. Titles, abstracts and subsequently full text of the articles were analyzed 
individually by two independent reviewers to determine whether they met the follow-
ing inclusion criteria: 1) the main subject of the article was DD; 2) the study used an 
original data-set of cases; 3) the study population consisted of at least five patients; 4) 
patients were 18 years or older. Only articles written in English, German, French or 
Dutch were included. If disagreement on inclusion of a publication arose a consensus 
between the two reviewers was met. If this disagreement persisted a third reviewer was 
consulted.
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Data extraction
Two reviewers independently extracted the data. Reported recurrence rates, definitions 
of recurrence and definitions that could be extracted from the text were identified. For 
example, in some studies, authors defined recurrence as the presence of new nodules 
or cords, without giving an explicit definition. Furthermore, characteristics such as 
authors, publication year or type of surgery were extracted.
comparing definitions using our dataset
To evaluate the effect of different definitions of recurrence found in literature, we 
applied the different definitions of recurrence on a single dataset of the Dupuytren 
Rotterdam Trial (Du Ro Trial) (NTR1692). This dataset consisted of preliminary data 
from patients who participated in the randomized controlled trial and were treated by 
limited fasciectomy or extensive percutaneous aponeurotomy and lipofilling (PALF) 
technique consists of extensive percutaneous aponeurotomy that completely disinte-
grates the cord and separates it from the dermis. Autologous fat from the abdomen is 
injected in the operated area. In a recent study, we described this technique in detail 
and published data from a initial cohort study (14). For the present study, we analyzed 
data from patients that were included in the Du Ro trial between May 2009 and Octo-
ber 2010. Medical ethical approval was obtained for this study and all subjects signed 
informed consent (MEC-2008-264).
We used the passive range of motion (ROM) data of the most affected digit, measured 
at two weeks and six months postoperatively. Extension goniometry was measured with 
all joints (MP, PIP and DIP) maximally extended. Further, peroperatively, the surgeon 
visually estimated the passive range of motion. Since all joints of the treated digits 
were measured with goniometry, the total passive extension deficit (TPED) could be 
calculated, representing the sum of joint angels of the MP-joint, PIP-joint and DIP-joint.
RESultS
literature search
The initial search resulted in the identification of 606 studies from PubMed and Embase. 
After analyzing the titles, abstracts and full text, 113 articles were included (Figure 
1). One article could not be found online or requested at the medical library of the 
Netherlands and medical library of England. Therefore this article was excluded from 
analysis(15).
Recurrence definitions
Of all 113 included articles describing a recurrence rate, only 56 articles described 
a definition of recurrence. Definitions found in the articles could be categorized into 
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three groups. Table 2 describes these definition categories, the corresponding studies 
and the exact definition used in the individual studies. The first category (type I) defines 
recurrent DD based on the return of disease (nodules or cords) in the operated area or 
in the operated hand (63% of all studies used this definition). The second category (type 
II) defines recurrent DD based on the return of contractures, with the minimal degree 
of contracture required for defining recurrence varying from 1 degree (‘any increase in 
contracture’) to 50 degrees (27%). The third category (type III) is based on the patient’s 
self report of a recurrence or based on whether a recurrent surgery was performed (10%).
Figure 2 summarizes the recurrence rates for the different treatment types and recur-
rence definition categories. The recurrence rates reported in the studies ranged from 0% 
to 100%. We found that all types of definition categories (I-III) were used for all types 
of treatments. However, articles on collagenase injections were the most consistent in 
the type of definition that was used (type II) (Figure 2 and Table 2).
Records identified through PubMed 
database searching 
(n = 442)
Records identified through Embase 
database searching 
(n = 536)
Records after duplicates removed
(n = 601)
Records screened
(n = 601)
Records excluded
(n = 401)
Full-text articles assessed 
for eligibility 
(n = 200)
Full-text articles excluded, 
with reasons 
(n = 86 + 1*)
Studies included in analysis
(n = 113)
figure 1: A flow chart of literature search is shown. PubMed and Embase were used to find articles 
about recurrence of Dupuytren’s disease. From the total 606 articles 113 articles were included for this 
study.
* Stankovic P; Early Surgery of Dupuytren Contracture/Fruhoperation einer Dupuytrenschen Kontraktur; 
Internist (Berl) 1997 (38); 482-483
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Applying the definitions on our dataset
We used data from 66 patients (56 males and 10 females) affected by primary DD 
from the Du Ro trial. Since the extensive percutaneous aponeurotomy and lipografting 
technique does not remove any tissue and since therefore a palpable nodule is always 
present in the operated hand, we could not apply the first definition category to our 
data.
Figure 3 shows the different recurrence rates when using different angular threshold 
for the category-2 definitions. The lower dark line represents the difference in joint 
angle between two weeks postoperative and six months postoperatively, analyzed in 
the most affected joint only. This recurrence rate strongly decreases from 49% when 
applying a change of five degrees in angle as the threshold for recurrence, to 2% when 
applying a 50 degrees threshold. The upper light-grey line, indicating the threshold in 
angle of the most affected joint when comparing peroperative data with the six months 
follow-up, shows the same pattern. Since more extension is measured peroperatively 
than at two weeks follow-up, higher recurrence rates are found. Because some authors 
used the total passive extension deficit (TPED), we added two extra lines for the TPED, 
showing a similar pattern compared to using the most affected joint only (Figure 3).
Since the Du Ro trial was not designed for this study purpose, patient-reported recur-
rence was not measured. Furthermore, this is an ongoing study and recurrent surgeries 
were not performed within six months of the initial operation. Therefore, the third 
definition category could not be evaluated using the Du Ro dataset.
Recurrence rate (%)
Radiotherapy
10020 40 60 800
Collagenase injections
Other
Fasciotomy
Fasciectomy
Fasciectomy + skingraft
1 1
1 1
11 11 1
1 1
1
1
1
1
1
1
11 1
2
2 2 2
22
2 212111 1 11111
2
33
2 2
2 13 123 3
3
3
figure 2: Graphical representation of all recurrence rates in literature, sorted by their corresponding 
treatment category. The numbers (1-3) represent the definition categories described in Table 2. The 
location of placement of the numbers indicates the percentage of the recurrence rate reported in the 
individual article. The grey lines indicate the range of recurrence rates reported for that specific treat-
ment category. Since not all articles reporting a recurrence rate also report a definition of recurrence, 
the grey lines sometimes exceed the location of the numbers.
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DIScuSSIon
Reporting recurrence rates is an essential part of evaluating the effectiveness of treat-
ment for DD(13). In this literature study, we found a wide range of different definitions for 
recurrence after treatment of DD. This resulted in recurrence rates within one dataset 
ranging from 2% to 86% when using different types of definitions. This study shows 
that the wide range of reported recurrence rates may largely be contributed by incon-
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figure 3: Relation between the acquired extension deficit and the recurrence rate in the single dataset. 
The extension deficit was based on the most affected joint per hand (n = 66). The lower dark line rep-
resents the difference in joint angle between two weeks postoperative and six months postoperatively. 
For example, when one degree extension deficit is applied as a threshold for recurrence, we found that 
55% of our patients had a change in angle that exceeded this threshold and that would therefore have 
a recurrence. With a 30 degrees threshold, however, only six percent of our cohort has a recurrence. 
The upper light-grey line indicates the same threshold in angle, however using peroperative data as the 
initial baseline data instead of data two weeks postoperative. Furthermore the TPED was used instead 
of the most affected joint. The vertical lines are the specific angular thresholds used in different articles; 
they indicate how these different thresholds lead to incomparable recurrence rates when applied to the 
same data. * Used TPED for the definition
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sistency in recurrence definitions. As a result, it is presently difficult or even impossible 
to compare recurrence rates between different treatments reported in the literature.
In this study, we found that 51% of the publications reporting recurrence rates did 
not present a definition of recurrence, while the remaining articles could be grouped 
into three main categories. In general, these categories are based on 1) the return of 
nodules and cords, 2) the return of joint contractures, or 3) the patient’s self-report 
of a recurrence or whether a recurrent surgery was performed. When visualizing all 
reported recurrence rates, we still found wide ranges even for the same treatment and 
definition categories (Figure 2). We found that recurrence rates at six months follow-up 
can range from 2 to 86% in the same dataset, based on applying different angular 
thresholds, different baseline measurement and different selected joints.
Most studies base definitions of recurrence on the reappearance of nodules or cords 
in the operated hand (category 1). While this may be suitable to define recurrences 
when performing a fasciectomy, it is less suitable when performing a needle aponeu-
rotomy or injecting collagenase since these techniques leave nodules and cords in 
place(16). This may explain why most of the recent trials on needle aponeurotomy and 
on collagenase injection use contracture-based definitions (category 2)(1-2). In addition, 
it can be argued that the return of nodules alone should not be the main aspect of 
a recurrence definition, since the indication for operation generally is not based on 
nodules or cords alone, but on the severity of the joint contracture(17).
Within category 2, angular threshold for defining recurrence varied from 1 to 50 de-
grees(10, 18). Our analysis shows that this threshold should be chosen carefully because 
of its great influence on the recurrence rate. Furthermore, while some authors describe 
recurrence as relapse of contracture of the treated finger in degrees relative to ‘normal’, 
they did not define ‘normal’(19-20). Since the maximum degree of extension is different 
in each person, this ‘normal’ should be carefully defined. Other authors compared the 
relapse of contracture at follow-up with the peroperative measurement or with the first 
measurement after surgery(1, 10). Within our dataset this difference alters the recurrence 
rate up to 20% (Figure 3). In contrast, our data showed little difference between using 
data of the most affected joint and using the TPED. A reason for this may be that the 
change in TPED is largely based on the change in the most affected joint (Figure 3).
literature database Search query
Pubmed (Dupuytren*[tw]) AND (reappear*[tw] OR recurr*[tw] OR return*[tw] OR 
predict*[tw] OR prognos*[tw] OR residu*[tw] OR remain*[tw] OR outcome*[tw]) 
AND (english[lang] OR dutch[lang] OR german[lang] OR french[lang])
Embase (Dupuytren*):de,ab,ti AND (reappear* OR recurr* OR return* OR predict* OR 
prognos* OR residu* OR remain* OR outcome*):de,ab,ti AND ([english]/lim OR 
[dutch]/lim OR [german]/lim OR [french]/lim)
table 1: Complete search strategy which was used for this study.
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The third category of definitions was based on the patient’s self-report of a recurrence 
or whether a recurrent surgery was performed. While the patients’ perceptive is an 
important indicator for operation and important to measure after intervention, it may be 
influenced by many factors, such as the patient’s overall satisfaction with the treatment 
process and the patient’s profession. Therefore, we suggest that patient’s perspective 
may be more suited as an addition to more objective definitions of recurrence. While 
the performance of recurrent surgery is also an important variable, the operation in-
dication may be influenced by many patient-related factors as well as the surgeons’ 
indication criteria.
Our study has a number of limitations. First, we excluded all articles to use for this 
review that were written in a language other than English, French, German or Dutch. 
We also excluded publications before 1985. However, overall, we believe that this 
will not have affected the main message of this study that definitions for recurrence are 
inconsistently used, leading to widely varying recurrence rates. Another limitation was 
that the data set used for the analysis was not constructed specifically for this study. 
Therefore, the definitions based on nodules and cords and those based on patients’ 
perception or operation indication could not be applied to our data. Despite of this, we 
feel that we were able to demonstrate the importance of a clear definition of recurrence 
and the effect of applying different angular thresholds for recurrence.
From the present study, it is clear that an international consensus on the definition of 
recurrence is needed to allow comparison of recurrence rates of treatments. The present 
review highlights a number of important points to consider for such an international 
consensus. First of all, since a number of recent treatments do not remove cords or nod-
ules, we suggest using a contracture-based definition in degrees. In such a definition, 
it is important to establish consensus which joints are evaluated. From this study, we 
suggest to evaluate the most contracted joint (MP or PIP) of the most contracted finger 
only. Including multiple joints or digits from a similar patient has well-described statisti-
cal problems(21). When using a contracture-based definition, postoperative long-term 
measurements should be related to early postoperative measurements (for instance 
after two weeks) since not all joints are completely corrected. In addition, peropera-
tive measurements lead to higher recurrence rates than postoperative measurement at 
two weeks. The angular threshold for recurrence is more or less arbitrary. However, it 
is important to have a threshold that is larger than the inherent measurement errors 
of goniometry of approximately five to ten degrees(22). As the angular threshold, the 
duration for the follow-up measurement may be more or less arbitrary but should be 
standardized. From a clinical point of view, longer follow-up measurement may express 
more precisely the amount or recurrent surgeries that are needed. However, from a 
research perspective, a one-year follow-up measurement may already show differences 
between techniques. In addition, it should be noted that dichotomizing recurrence as 
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a “yes” or “no” per patient reduces the amount of information compared to reporting 
exact angular changes in degrees per patient. A more sensitive measure could therefore 
be to compare the change in joint contracture between groups over time, leading to a 
higher statistical power.
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AbStRAct
Background: One of the major determinants of Dupyutren disease (DD) treatment effi-
cacy is recurrence of the contracture. Unfortunately, lack of agreement in the literature 
on what constitutes recurrence makes it nearly impossible to compare the multiple 
treatments alternatives available today. The aim of this study is to bring an unbiased 
pool of experts to agree upon what would be considered a recurrence of DD after treat-
ment; and from that consensus establish a much-needed definition for DD recurrence.
Methods: To reach an expert consensus on the definition of recurrence we used the 
Delphi method and invited 43 Dupuytren’s research and treatment experts from 10 
countries to participate by answering a series of questionnaire rounds. After each round 
the answers were analyzed and the experts received a feedback report with another 
questionnaire round to further hone in of the definition. We defined consensus when at 
least 70% of the experts agreed on a topic.
Results: Twenty-one experts agreed to participate in this study. After four consensus 
rounds, we agreed that DD recurrence should be defined as “more than 20 degrees 
of contracture recurrence in any treated joint at one year post-treatment compared 
to six weeks post-treatment”. In addition, recurrence should be reported individually 
for every treated joint and afterwards measurements should be repeated and reported 
yearly.
Conclusion: This study provides the most comprehensive to date definition of what 
should be considered recurrence of DD. These standardized criteria should allow us to 
better evaluate the many treatment alternatives.
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IntRoDuctIon
Recurrence of disease following any technique to correct the contractures is one of the 
major setbacks in the treatment of Dupuytren’s disease (DD). Since present techniques 
only treat the symptoms of this chronic and progressive disease, recurrence over time 
is inevitable in the majority of patients. Therefore, assessment of recurrence rates is 
an essential element in describing and comparing the efficacy of different treatment 
options for DD.
Two separate systematic reviews have recently identified dire need for consensus on 
how to define recurrence of DD(1, 2). This lack of a clear definition may partly explain 
why reported recurrence rates vary from 0% to 100%(3-8). In addition, we have shown 
that applying the different definitions on a single dataset can change the resulting recur-
rence rates from 2% to 86% (Figure 1)(1).
To obtain an internationally accepted and wide supported definition of recurrence for 
DD, a consensus agreement based on the experience and knowledge of an international 
group of renowned experts is needed. Therefore, the goal of this international study was 
to develop consensus on a single definition of recurrence of DD that is applicable in 
clinical and research settings.
mEtHoDS
In this study we used the Delphi method, which is designed to reach consensus between 
individuals using questionnaire-based surveys(9). Experts in the field of Dupuytren’s 
disease (DD) were invited to participate in our Delphi study. To identify these experts, 
we selected all clinical DD-related PubMed articles that were published between 2005 
and 2012. In addition, we used the articles from our systematic review to identify 
experts in the field of DD(1). Either the first or last author of each article, based on the 
number of publications in the field of DD, was invited to participate. When multiple 
experts were identified from the same institution, only the most experienced expert 
was invited to participate. We excluded experts that did no longer participate in the 
field, for example due to retirement, or authors who published only a single DD-related 
paper.
In November 2012, 42 experts from ten countries in four continents were invited to 
participate. All experts were provided with information on the Delphi study as well as 
with a draft of our systematic review. Following Delphi guidelines, 51% agreement 
is considered consensus. However, we aimed for a minimal of 70% agreement for 
consensus. The identities of the other participating experts were not disclosed to the 
experts during the process.
In the first round, experts were asked to score the relevance of four different dimen-
sions of recurrence to be included in a single definition of DD recurrence (first two 
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columns of Table 1) using a zero to ten numerical scale and multiple choice questions. 
For example, we asked “On a scale from zero to ten, how important is it to include the 
return of Dupuytren’s nodules based on palpation or visual inspection in the definition 
of recurrence?” After each question, the experts could add a comment or explanation.
The first two authors analyzed the results and discussed the outcomes with the other 
authors. If 70% of the experts scored five or higher, the item was considered important 
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figure 1: Relation between the acquired extension deficit and the recurrence rate in the single dataset. 
The extension deficit was based on the most affected joint per hand (n = 66). The lower dark line rep-
resents the difference in joint angle between two weeks postoperative and six months postoperatively. 
For example, when one-degree extension deficit is applied as a threshold for recurrence, we found that 
55% of our patients had a change in angle that exceeded this threshold and that would therefore have 
a recurrence. With a 30 degrees threshold, however, only six percent of our cohort has a recurrence. 
The upper light-grey line indicates the same threshold in angle, however using peroperative data as the 
initial baseline data instead of data two weeks postoperative.
Furthermore the TPED was used instead of the most affected joint. The vertical lines are the specific 
angular thresholds used in different articles; they indicate how these different thresholds lead to incom-
parable recurrence rates when applied to the same data. * Used TPED for the definition
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for further consideration. These included items were discussed more in-depth in the 
following rounds.
In each following round, we provided feedback to the experts by summarizing the 
answers on the previous round in combination with a synopsis of anonymous com-
ments. After this feedback, we asked the experts to answer each question again on 
which consensus was not yet reached. Topics on which consensus was reached were 
also presented but only with the opportunity for the experts to give additional com-
ments. If experts did not complete a previous round before the deadline, they were still 
invited to the next round.
RESultS
Twenty-one experts (64%) from 10 countries participated in this study: seven from North-
America, 13 from Europe, and one from Australia. A total of four rounds were needed to 
reach consensus. The response rate varied per round between the 76% and 90% (Figure 2).
A first dimension scored by the experts was location of recurrence. Consensus was 
that recurrence of Dupuytren’s disease (DD) should be located in the operated area only 
in order to differentiate recurrence from disease extension to other joints. In addition, 
since DD can affect multiple joints, fingers and hands, consensus was that recurrence 
should be measured in all treated joints, fingers and hands regardless if full extension 
was reached during treatment. Experts also reached consensus that all treated joints 
should be scored individually to count as a recurrence rate (Table 1).
The second dimension was whether a recurrence should be assessed based on the 
presence of nodules, cords and/or joint contractures. Experts agreed DD nodules and 
cords should not be explicitly taken into account, furthermore a recurrent joint contrac-
ture of at least 20 degrees in one joint is needed for a recurrence.
A third dimension was the timing of baseline measurements and follow-up. Experts 
agreed recurrence should be measured at one year post-treatment and should be com-
Dimensions consensus % Experts
1 Location of recurrence All treated joints 70% - 80%
2
Inclusion of nodules, cords and 
contractures
20° contracture 86%
No modules or cords 56% - 60%
3
Baseline measurements and 
follow-up
6 weeks post treatment 79%
1 year post treatment 86%
4
Patient characteristics & Patient-
reported recurrence
Excluded 75%
table 1: The dimensions (numbered 1- 4) were presented to the experts and the resulting consensus 
on each dimension is presented. The last column shows the percentage of experts that agreed on each 
consensus or a range of percentages, when the outcome differed in more than one round of the Delphi 
study.
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43 experts from 10 countries on 4 continents
Asia (JPN), Europe (BEL, DEU, FRA, GBR, NLD, POL, SWE), 
North America (USA), Oceania (AUS)
21 experts from 9 countries on 3 continents
Europe (BEL, DEU, FRA, GBR, NLD, POL, SWE), 
North America (USA), Oceania (AUS)
responded to a computer-based 
questionnaire containing 14 questions 
about 4 different dimensions
22 experts 
did not respond and were excluded
First Round
Second Round
Fourth Round
Third Round
19 experts responded to a computer-based questionnaire
containing 7 questions about 3 different dimensions
16 experts responded to a computer-based questionnaire
containing 6 questions about 2 different dimensions
16 experts responded to a computer-based questionnaire
containing 3 questions about 2 different dimensions
All 21 experts agreed to the final definition 
figure 2: Figure shows the number of experts who were included in the study rounds and their country 
of origin.
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pared to a baseline measurement. Consensus was that intra-operative measurements 
should not be used as a baseline value and, therefore, an assessment at six weeks 
after treatment was selected as a baseline. Since it is presently unclear from literature 
how recurrence develops over time, experts agreed to recommend yearly repeated 
measurements when feasible.
A fourth dimension consisted of scoring patients’ characteristics, such as diathesis 
and patient perception of recurrence. Although it is clear that diathesis has a significant 
influence on recurrence, the experts agreed that information on diathesis should not 
be included into the definition, although it should be scored in every study. The experts 
also agreed that, while patient-rated information about recurrence can be relevant, it 
should not be included in a single definition of recurrence of DD.
After the last round, all 21 experts agreed to define recurrence of Dupuytren’s disease 
after treatment as “an increase in joint contracture in any treated joint of at least 20 de-
grees at one year post-treatment compared to six weeks post-treatment”. Additionally, 
although not part of the definition, the experts advised the community to 1) conduct 
studies that repeat measurements yearly to study the development of recurrence, and 2) 
measure and report recurrence rates for all treated joints individually (Table 2).
Patient Hand Joint
Extension deficit 
prior treatment 
(degrees)
Extension deficit 
6 weeks post 
treatment (degrees)
Extension deficit 1 
year post treatment 
(degrees)
Recurrence
(yes / no)
Recurrence 
rate (%)
1
Left
MP 4 60 10 10 No
5/14 joints 
= 36%
MP 5 75 0 20 Yes
Right
MP5 20 0 0 No
PIP 5 90 40 60 Yes
2 Left
MP 5 30 10 15 No
PIP 5 80 20 35 No
3 Right
MP 4 10 0 10 No
MP 5 15 0 15 No
PIP 5 40 0 20 Yes
4 Left PIP 5 90 10 25 No
5 Left
MP 3 60 10 30 Yes
MP 4 40 0 15 No
MP 5 30 0 15 No
PIP 5 60 5 25 Yes
table 2: A fictitious cohort of patients with Dupuytren’s disease is presented and the table shows when 
recurrence has occurred by using the consensus definition. It also shows the recurrence rate that should 
be described in the paper.
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DIScuSSIon
Since the present lack of a consensus for recurrence of Dupuytren’s Disease makes it 
impossible to compare results between different studies, we conducted this interna-
tional study to obtain consensus on a universal definition for recurrence of DD after 
treatment. Based on this, we propose to define recurrence of DD after treatment as 
“an increase in joint contracture in any treated joint of at least 20 degrees at one-year 
post-treatment compared to six weeks post-treatment“.
The definition established in this study was obtained by evaluation four different di-
mensions of recurrence. The first dimension was location of recurrence. Consensus was 
that only the operated or treated area should be considered and that all treated hands, 
fingers and joints should be included to calculate recurrence rates, which allow to 
distinguish recurrence (in the same area) from disease extension (outside of the treated 
area). In addition, although additional measures such as a total passive extension deficit 
(TPED) can also be of value, consensus was that individual joint measurements should 
be used primarily. One expert stated: ‘TPED is measured while all joints are being 
simultaneously passively extended. As such, it represents fixed joint contractures. This 
will yield a different measurement than the sum of measurements made of individual 
joint passive extension, while the proximal joint or distal joints in that same ray are 
allowed to flex.’ Furthermore, a disadvantage of a TPED is that it includes non-affected 
joints and newly affected joints (disease extension), creating possible false-positive 
recurrence rates.
A second dimension considered including palpable nodules, palpable cords and 
contractures in the definition of recurrence. The experts unanimously agreed to include 
increase of contracture in the definition of recurrence. Furthermore, they agreed to 
exclude nodules and cords. The angular threshold for the contracture to be considered 
a recurrence was set at 20 degrees. There were two reasons for this threshold. Firstly, 
inherent measurement errors of goniometry are approximately 5-10 degrees and there-
fore a larger threshold is needed(10). Secondly, 15-20 degrees is often considered an 
indication for a new intervention, for example in the Hueston Table-top test(11).
The exclusion of the presence of nodules and cords in the definition was more con-
troversial in our group of experts. While the main reason to include palpable nodules 
and palpable cords in the definition was that reappearing nodules and cords are the 
earliest signs and often the cause of recurrence, the majority of the experts mentioned 
three main reasons to exclude palpable nodules and palpable cords in the definition. 
Firstly, nodules and cords by themselves very seldom cause any disability, or require 
surgical treatment. Secondly, minimal invasive techniques are meant to disconnect 
Dupuytren tissue that forms cords or nodules. However, these cords and nodules are 
left in place during these techniques(5, 12). This makes it difficult to identify newly formed 
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nodules and cords because the old ones remain. Thirdly, it is challenging to reliably 
identify the presence of nodules and cords in the presence of post-surgical scarring.
A third dimension considered timing of baseline and follow-up measurements. 
Consensus was to perform baseline measurements at six weeks post treatment, mainly 
because experts concluded that wound healing takes time following surgery. Further-
more, hand function will return in approximately two to four weeks and it also has 
been demonstrated that the results at six weeks post treatment were better compared 
to one-week post treatment(13, 14). Therefore, six weeks was considered a first time-point 
evaluation for treatment success. The follow-up time was more controversial. Experts 
mentioned from a clinical point of view, longer follow-up measurements might express 
more precisely the amount of recurrent treatments that are needed. However, from a 
research perspective, a one-year follow-up may already express the main differences 
between techniques. One expert stated: ‘recurrence progresses with time. But this 
progression is non-linear. Either our scientific community develops standardized time-
to-recurrence charts, or we all decide to evaluate all patients at a given point in time.’ 
After four rounds, consensus was to measure recurrence after one year. In addition, the 
experts advised yearly repetition of measurements in studies that cover multiple follow-
up years since more knowledge is needed on how recurrence progresses over time.
A last dimension included patient characteristics and patients’ perception. Consensus 
was that patient factors (e.g. diathesis) can predict the risk of developing recurrence, 
but are not a characteristic of recurrence itself(15). Therefore, it was excluded. In ad-
dition, while all experts concluded that patients’ perception is very important, it was 
also excluded(16). One experts stated ‘while we can pat ourselves on the back for a 
great range of motion improvement, or feel we did not achieve our goal, the patient’s 
own perception is the bottom line of what matters the most. Unfortunately, we do not 
have very objective measures (of subjective improvement) and any measure will be 
invariably affected by factors unrelated to the medical treatment delivered’. Since, there 
are no objective measures to measure patients’ perception about recurrence, it is not 
included in this definition.
Our study has a number of weaknesses and strengths. Firstly, only the minimal 
amount of experts generally assumed to be needed for a Delphi study participated in 
our study(9). Unfortunately the invited experts from the Asian continent did not respond 
and are therefore not represented in this Delphi study. However, all responded experts 
represent countries from all over the world and are clearly renowned in the field. Experts 
completed all rounds with an average response rate of 80% and, at the end of the pro-
cess, all experts agreed on the final definition of recurrence. Secondly, this Delphi study 
was conducted with computer-based questionnaires. A disadvantage of this method 
is that it lacks the ability to stimulate discussion and can lead to misinterpretation of 
comments given by experts. On the other hand, computer-based questionnaires allow 
Chapter 3
52
anonymous responses from the experts, and thus avoiding possible peer-pressure. A 
third limitation was that the goniometric measurement protocol needed for this defini-
tion was not part of the Delphi consensus rounds. To our knowledge, an internationally 
recognized guideline for measuring joint angle is presently lacking. In our experience, 
most researchers and clinicians measure joint angle dorsally(17). As some of the experts 
as well as a reviewer of this manuscript have correctly noted, it is important to control 
for the adjacent joints when measuring a specific joint, especially when a cord spans 
multiple joints. Fortunately, since the present definition is based on a change in joint 
angle of time, differences between goniometric measurement techniques may lead to 
different absolute angles, but difference may be much smaller when analyzing the 
change in joint angle over time. A final limitation is that while our goal was to obtain 
one clinically relevant and easily applicable definition for recurrence of DD after treat-
ment, it may not be possible to reflect the complexity of recurrence of DD in this single 
definition. Table 2 shows an example of how a typical dataset from a clinical study 
should be interpreted to calculate a recurrence rate. From this table, it is also clear that 
this single recurrence rate does not capture the complexity of the data. Therefore, we 
do not advocate researchers to only use this single measure, but we do advocate this is 
the minimal measure to report. Additional secondary measures may be needed to also 
describe the presence of the disease or disease extension, for example the presence 
of palpable nodules and cords. Also, in addition to using a threshold for recurrence, it 
could also be valuable to describe the average change in joint angle between baseline 
and follow-up or to report recurrence rate per joint separately.
In conclusion, we present a uniform definition that for the first time allows compari-
son between future studies, thereby improve our understanding of the effectiveness of 
different treatment methods.
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AbStRAct
Background: While in modern medicine, patients’ preferences are important, these 
have never been defined for characteristics of Dupuytren treatment. This study deter-
mines these patients’ preferences using a discrete choice experiment.
Methods: A multicentre discrete choice experiment study was conducted among pa-
tients with Dupuytren’s disease who had been previously treated. Patients were asked 
on their preferences for attributes of Dupuytren treatments using scenarios based on: 
treatment method, major and minor complication rates, recurrence rates, convales-
cence, residual extension deficit after treatment and aesthetic results. The relative 
importance of these attributes and the trade-offs patients were willing to make between 
them were analysed using a panel latent class logit model.
Results: Five-hundred-and-six patients filled in the questionnaire. All above-mentioned 
attributes proved to influence patients’ preferences for Dupuytren treatment (p<0.05). 
Preference heterogeneity was substantial. Males who stated to perform heavy labour 
made different trade-offs than females or males who did not perform heavy labour. In 
general, recurrence rate (36%) and extensive deficit (28%) were the most important 
attributes in making treatment choices, followed by minor complication rate (13%). 
Patients accepted an increase of 11% recurrent disease if they could receive needle 
aponeurotomy (NA) treatment instead of limited fasciectomy.
Conclusion: This study confirms the importance of low recurrence rates and complete 
contracture corrections, but also emphasizes the significance of low complication rates. 
Convalescence was not an attribute, which scored high. The preference heterogeneity 
shows that patient consultations need to be targeted differently, which may result in 
different treatment decisions depending on patient characteristics and preferences.
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IntRoDuctIon
While many surgeons may still consider limited fasciectomy (LF) as the golden standard 
for treating Dupuytren’s disease, in recent years, minimal invasive techniques, espe-
cially needle aponeurotomy (NA) and collagenase, have become increasing popular(1-5). 
The most optimal of these techniques cannot easily be decided, since each technique 
has specific strengths and weaknesses. For example, collagenase is a minimal-invasive 
strategy with shorter recovery time but may have higher recurrence rates than the more 
invasive LF(2, 3, 6). In addition, NA also has a shorter recovery time than LF, but has a 
much higher minor complication and recurrence rate(2, 7).
Due to these different pros and cons of present techniques, the decision which treat-
ment method is preferred to treat patients with DD depends on the relative importance 
of these factors. Amongst others, degree of contracture, expertise of the surgeon, ex-
pected commitment of the patient to the postoperative care and follow-up and patients’ 
expectations may all play an important role in this choice(8, 9). In addition, data on 
recurrence rates, surgical outcome and complication rates play an important role in 
advice to patients and in clinical decision making(10).
At present, it is unclear how a patient would weigh a better reduction in contracture 
correction compared to an increase in the major complication rate or to what extend 
patients were willing to accept an increase in recurrent disease for a reduction in dura-
tion of recovery. Insight in these preferences can contribute to patient-centred care 
and information for patients. Therefore, the aim of this study is to determine which 
treatment attributes are important for patients when choosing a DD treatment option 
and to what extent patients are prepared to make trade-offs between these attributes.
mEtHoDS
Discrete choice Experiment
To quantify patients’ preferences for health care interventions, discrete choice experi-
ments (DCEs) are increasingly used(11). DCEs assume that health care interventions can 
be characterized by a combination of attributes (e.g. degree of contracture correction, 
complication rates) and attribute levels (e.g. major complication rates: 2%, 5%), and 
that this combination determines patients’ preferences(12). In a DCE, respondents are 
repetitively offered hypothetical choices between two or more alternative health care 
interventions, which are presented as different combinations of attribute levels(13, 14).
Attributes and attribute levels
To define possible attributes and their levels for this DCE study, we conducted a litera-
ture study to evaluate which outcomes parameters are evaluated in clinical studies(1-3, 
6, 7, 15-17). Furthermore, experiences from the Dupuytren Rotterdam (Du Ro) trial and 
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the expert opinion of two hand surgeons from the Erasmus University Medical Centre 
(Erasmus MC) were used for establishing attributes. In total, seven relevant attributes 
with their levels were determined: (1) treatment method, (2) major complication rate (3) 
minor complication rate, (4) convalescence, (5) recurrence rate, (6) degree of residual 
contracture after correction, and (7) aesthetic result (Table 1).
Study design and questionnaire
The combination of five attributes with three levels and two attributes with four levels 
resulted in 3.888 hypothetical treatment alternatives. As it is not feasible to present a 
single patient with all alternatives, an efficient DCE design by maximizing D-efficiency 
(using Ngene software, version 1.1.1, http://www.choice-metrics.com/) was created 
with 24 choice sets to estimate all main effects. Since response reliability decreases 
with more than 16 choice-sets per respondent, we used a blocked design dividing these 
24 choices into two questionnaires(18, 19).
Attributes and Attribute levels
Attributes Levels
Treatment method Limited fasciectomy
Needle aponeurotomy (NA)
Extensive percutaneous aponeurotomy and lipofilling (PALF)
Collagenase injections
Major complication rate 2%
5%
10%
Minor complication rate 5%
20%
60%
Convalescence 5 days
30 days
60 days
Recurrence rate within 5 years 30%
60%
90%
Residual extension deficit after treatment 0 degrees
20 degrees
40 degrees
60 degrees
Aesthetic result Moderate
Good
Excellent
table 1: DCEs assume that health care interventions can be characterized by a combination of attributes 
and attribute levels. This table shows the different attributes and levels that are used in this study.
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Each questionnaire consisted of 12 choice-sets (Figure 1). One choice-set was repeat-
ed in all subjects to check for consistency. Each choice-set consisted of two treatment 
options for DD and a ‘no treatment’ option to allow an ‘opt out’. The questionnaire was 
specifically designed not to favour any type of treatment option using an unlabelled 
DCE design(20).
Characteristic
Treatment method
Treatment CTreatment BTreatment A
No treatmentSurgeryNeedle aponeurotomy
5 %Possibility of major 
complication
5% 0%
20%
Possibility of 
recurrence 
within 5-years
Possibility of minor 
complication
20% 0%
90% 30% n.a.
Straigthness of the 
finger(s) after 
treatment
60 degrees0 degrees n.a.
Convalescence 
Aesthetic result
0 days30 days30 days
n.a.moderateexcellent
Treatment option
Attribute
Choice set
Level
Opt out
figure 1: This figure shows an example of a choice set. Patients received 12 different choice sets in order 
to measure their preferences. It was explained that if ‘opt out’ was chosen it would indicate that the 
disease would progressively worsen.
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To evaluate if patients were able to interpret the questions, three sample questions 
at the beginning of the questionnaire were asked. This was examined as a pilot in 26 
patients.
Attached to the questionnaire was a detailed description of the attributes and their 
levels. Photographs were included to demonstrate ‘moderate’ aesthetic result, ‘good’ 
aesthetic result and ‘excellent’ aesthetic result. We defined minor complications as 
hematoma, oedema and mild pain complaints whereas major complications included 
tendon injury, nerve injury, arterial lesions, and complex regional pain syndrome 
(CRPS). General questions about history of DD, satisfaction with previous treatment, 
profession and level of education were asked in an additional questionnaire.
Study sample
This multicentre DCE study was conducted at Erasmus MC and Sint Franciscus Gast-
huis (SFG) and at seven locations of the Xpert Clinic in the Netherlands. Patients who 
received any kind of treatment for DD between January 2009 and August 2012 were 
included. These patients received either LF with or without skin graft, extensive per-
cutaneous aponeurotomy and lipofilling (PALF), NA, injection with collagenase or a 
combination of these treatments.
Invitations were sent to all patients. Patients could either fill in a web-based version 
of the questionnaire or a paper copy. A reminder was sent after 6 weeks to all non-
responders.
This study received approval by the Medical Ethical Committee of Erasmus MC in 
Rotterdam (MEC-2012-330). All patients gave their informed consent.
Statistics
We used a panel latent class logit model for the analysis of patients’ choices(21, 22). This 
latent class logit model is a conditional logistic regression analysis that can identify 
whether different groups with similar preferences (class segments) exist in the popula-
tion. The model is flexible in that the probability that sampled respondents belong to a 
particular class can be linked to covariates (e.g. gender, manual labour and treatment 
history); hence allowing for some understanding as to the makeup of the various class 
segments(22). The latent class logit model accounts for the panel nature of the data in 
which each respondent completed 12 choice tasks. To determine the number of classes, 
we selected the model with the best fit based on the Akaike information criterion (AIC). 
We tested a number of different specifications for the utility function (i.e., categorical or 
numerical attribute levels) and found that the optimal utility function was:
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Vnsj = β0|c + β1|c treatment_palfnsj|c + β2|c treatment_needlensj|c + β3|c treatment_
collegenasensj|c β4|crisk of major complicationsnsj|c + β5|crisk of minor complicationsnsj|c 
+ β6|cconvalescence (days)nsj|c + β7|crisk of recurrence within 5-yearsnsj|c + β8|cresidual 
extension deficit after treatmentnsj|c + β9|caesthetic result_goodnsj|c + β10|caesthetic re-
sult_very goodnsj|c
Where:
Vnsj|c  represent the observable utility that respondent n belonging to class segment 
c has for alternative j in choice set s;
β0|c represents an alternative-specific constant for a certain class;
β1-10|c  are class-specific parameter weights (coefficients) associated with each at-
tribute (level) of the DCE;
Hence, all attributes were acted as linear attributes, except for the attributes treatment 
method and aesthetic results (both categorical variables). The reference levels for ‘treat-
ment method’ and ‘aesthetic results’ were ‘surgery’ and ‘moderate’, respectively.
Interpretation of the coefficients:
1) The statistical significance of a coefficient (p-value ≤ 0.05) indicated that, condi-
tional on belonging to that class, respondents considered the attribute important 
when making stated choices.
2) In terms of the class assignment parameters (i.e., the covariates), statistically sig-
nificant parameter estimates indicate that the covariate can be used to distinguish 
between the different classes. For example, if the covariate male gender is negatively 
and significantly associated with a particular class in the assignment model, then it 
is indicative that men are less likely to belong to that particular class than women.
3) The sign of the coefficient reflects whether the attribute had a positive or negative 
effect on preference for a treatment.
4) The value of each coefficient represents the importance respondents assign to an 
attribute (level). However, different attributes utilize different units of measurement. 
For example the coefficient ‘major complication rate’ represented the importance 
per 1% complication rate. When looking at a treatment that generates 5% protec-
tion rate, the coefficient must be multiplied 5 times (5 times coefficient of ‘major 
complication rate of a treatment’ of 1% = coefficient of ‘major complication rate of 
a treatment’ of 5%).
We used NLogit 4.0 software (www.limdep.com) to estimate the latent class models 
and SPSS 21.0 software (http://www-01.ibm.com/software/analytics/spss/) for all other 
analysis.
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Importance scores and trade-offs
We translated the preference coefficients of all attributes to importance scores and the 
clinically relevant trade-offs. This will give us more information about which attribute 
was most important and the willingness to trade different attribute levels for ‘recur-
rence rate’ and ‘contracture correction’. In more detail, we calculated class specific 
importance scores (IS) to visualize the relative importance of a given attribute in that 
class by dividing the difference in utility between highest and lowest level for a single 
attribute by the sum of the differences of all attributes for that class(13). Hence, the IS are 
calculated rates, indicating how much one decision is based on a specific attribute (e.g. 
x% of the decision for a specific treatment option is based on recurrence rate, and y% 
of the decision is based on reduction of extension deficit; all rates together count up to 
100% and counts as 1 decision for a specific treatment). Additionally, we determined 
the ranking IS of each attribute. That is, an attribute with a ranking IS of 1 represents 
the most important attribute, while an attribute with a ranking IS of 7 represents the 
least important attribute. Furthermore, we also calculated overall importance scores, 
by taking class probability into account.
Additionally, we calculated the willingness to trade different attribute levels for ‘re-
currence rate’ and ‘contracture correction’ by taking the ratio of the coefficients of the 
different attributes with ‘recurrence rate’ or ‘contracture correction’ as the dominator. 
For example, a value that represents how much change of recurrence or reduction 
of contracture correction a patient is willing to sacrifice for one unit change in the 
attribute of interest (e.g. major complications). Confidence intervals of this trade-off 
were estimated using the Krinsky and Robb procedure(22, 23).
RESultS
Participants
A total of 506 out of 973 patients (59%) filled in the questionnaire. One-hundred-thirty-
three patients did not want to participate in the study. Furthermore, we were not able to 
contact eight patients due to wrong postal addresses. Sixty-seven patients either did not 
return or completed the questionnaire. Two-hundred-fifty-nine patients did not respond 
at all (26.6%). In total, 393 men and 113 women participated in this study. The mean 
age of the population was 64 years old. This study population is comparable to patients 
suffering of DD, who visit the outpatient clinic (Table 2).
Discrete choice experiment results
Three groups in the latent class model were identified (Table 3), indicating that three 
different choice patterns could be identified between the different patients. The prob-
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ability to belong to one of the three groups within the sampled population was 0.40, 
0.11 and 0.49 for latent classes 1, 2, and 3, respectively.
The probability to belong to a specific class was dependent on two socio-demographic 
variables: gender and conducting heavy manual labour. More specifically, males con-
ducting manual labour more frequently belonged to class 2. Other socio-demographic 
variables were not significantly explaining class assignment probabilities.
baseline characteristics
Respondents (N = 506)
Characteristics
Mean age + SD (years) 64(9)
Sex
 male
 female
393
113
78%
22%
Education level
 low
 intermediate
 high
63
218
225
12%
43%
45%
Civil class
 married / living with partner
 partner, living apart
 single / divorced
 widow(er)
433
12
44
17
86%
2%
9%
3%
Heavy manual labor
 yes
 no
142
364
28%
72%
Family with Dupuytren’s disease (DD)
 first / second degree
 third / fourth degree
 no family member with DD
 not clear
248
16
147
95
49%
3%
29%
19%
Ectopic disease
 M. Ledderhose
 M. Peyronie
 M. Ledderhose and M. Peyronie
 no ectopic disease
79
16
8
403
15,5%
3%
1.5%
80%
Previous treatment
 surgery *
 minimally invasive technique **
 surgery and minimally invasive technique
273
123
110
54%
24%
22%
table 2: In this table the patients’ characteristics are mentioned.
* limited fasciectomy and dermofasiectomy
** needle apeneurotomy (NA), extensive percutaneous apeneurotomy with lipofilling (PALF), collage-
nase
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Overall, almost all coefficients of the linear attributes were significant. Preference 
for a certain treatment decreased (indicated by a negative coefficient) with increasing 
major and minor complication rates, longer convalescence, higher recurrence rate and 
larger post-treatment extension deficit. The coefficients of the categorical attributes (i.e., 
treatment method and aesthetic results) showed that (I) in latent class 1 and 3 the effect 
of preferring NA was significantly higher than surgery (0.171 vs −0.005, and 0.444 vs. 
−0.106, for latent class 1 and 3 respectively); (II) in latent class 2 the effect of preferring 
surgery was significantly higher than PALF (0.951 vs. −0.948); (III) in all latent classes a 
very good aesthetic result was preferred over a moderate aesthetic result.
Importance scores
The relative importance of the different attributes, as described by the importance scores 
in Table 3 were different between the subjects belonging to the different latent classes. 
Subjects in class 1 predominantly made their choice based on extension deficit (50%) 
and recurrence rate (27%). In class 2, subjects chose primarily based on recurrence 
(29%), treatment method (28%), and residual contracture (22%). In class 3, subjects 
made their choice predominantly on recurrence (44%) and minor complication (19%). 
Overall, recurrence rate (36%) and residual contracture (28%) were the most important 
attributes determining treatment choice.
trade-offs
In Table 4 trade-offs are presented that patients were willing to make for ‘recurrence of 
disease’ and ‘contracture correction’. Amongst others, patients accepted an increase of 
10.5% recurrent disease if they could receive NA treatment instead of LF. Furthermore, 
patients were willing to accept an increase of two percent for getting recurrent disease 
for a reduction of one percent of major complications; this means they accept an 
increase of 10% of recurrent disease for a reduction of five percent in major complica-
tions. In addition, for every 9 degrees increase of residual contracture after treatment, 
patients were willing to trade 10% less risk of recurrent disease.
DIScuSSIon
The aim of this study was to determine which attributes are important for a patient 
when choosing a DD treatment option and to what extent a patient is willing to make 
trade-offs between characteristics of treatment options. We found that treatment 
method, major complication rate, minor complication rate, convalescence, recurrence 
rate, degree of residual contracture after treatment, and aesthetic result, all proved to 
influence patients’ preferences for Dupuytren treatment. Preference heterogeneity was 
substantial. Males who stated to perform heavy labour made different trade-offs than 
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females or males who did not perform heavy labour. Overall, recurrence rate (36%) 
and extensive deficit (28%) were the most important attributes in making treatment 
choices, followed by minor complication rate (13%). Patients accepted an increase of 
11% recurrent disease if they could receive NA treatment instead of LF.
Our study has a number of specific strengths and limitations. The main strengths 
of this study are the large study population (506 analysed questionnaires) and the 
thorough and state-of-the-art design and analysis of the DCE. Furthermore, in this study 
we included patients already treated for DD because they are familiar with the disease 
and the impact of a surgical or minimal invasive surgery. However, this strength is 
also a limitation. Because patients were previously treated, they may have ‘defended’ 
their own treatment (i.e. cognitive discordance), or they may have previous positive 
or negative treatment experiences. This may have biased our results. On the other 
hand, they represent the general population that visits the outpatient clinic. However, 
when comparing patients that received different treatments previously, we found no 
specific choice-pattern based on the prior surgeries. This indicates that patients previ-
ously treated by an invasive surgery made no other choices than patients treated with 
a minimal invasive technique. In other words, we believe these study outcomes are 
valid and therefore relevant for future practice and further understanding of patients’ 
preferences. Additionally, although we did not find evidence for cognitive discordance, 
we recommend repeating the study for patients not having been treated for DD to 
determine the robustness of our results. A second limitation is, inherent to DCE where 
willingness to trade attributes
Attribute
Willingness to trade 
recurrence (%;CI)
Willingness to trade 
extension deficit 
(degree; CI)
With
Treatment method
−9.8 (−12.5 to −7.4)* −8.45 (−11.1 to −6.2)* PALF instead of surgery
10.5 (8.0 to 13.2)* 9.0 (6.7 to 11.8)* NA instead of surgery
−2.5 (−4.6 to 0.4) 2.2 (0.4 to 4.0)* collagenase instead of surgery
Major complication 
rate
2.0 (1.7 to 2.3)* 1.7 (1.4 to 2.0)* 1% less risk of major complicatons
Minor complication 
rate
0.5 (0.4 to 0.5)* 0.4 (0.3 to 0.5)* 1% less risk of minor complications
Convalescence 0.2 (0.3 to 0.3)* 0.2 (0.1 to 0.2)* 1 day faster recovery
Recurrence rate n.a. 0.9 (0.8 to 0.9)* 1% less risk of recurrence
Extension deficit 1.2 (1.1 to 1.3)* n.a. 1% less residual extension deficit
Aesthetic results
1.0 (−0.7 to 2.6) 0.8 (−0.7 to 2.2) good instead of moderate result
4.8 (3.1 to 6.5)* 4.1 (2.7 to 5.7)* excellent instead of a moderate result
table 4: This table shows the results of the trade-offs patients were willing to make. For example, pa-
tients were willing to accept an increase of two percent for getting recurrent disease for a reduction of 
one percent of major complications. 
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a larger number of attributes are important, that discrete choice questionnaires can 
be difficult to understand for patients. Due to the high number of attributes, patients 
may have difficulty overseeing all attributes and their levels when asked to select a 
specific treatment. Therefore, to evaluate the task understanding, we repeated one of 
the questions in the questionnaire at the end. This consistency test showed that 19% 
of the patients did not answer the question consistent. However, we found that these 
participants had patient characteristics (gender, age etc.), and similar preferences com-
pared to the group that correctly answered the consistency question. Therefore, we did 
not exclude this group from the study population.
Unfortunately, few comparative studies are available to compare the attribute levels of 
different treatments within the same population and with the same measurement proto-
col. We showed that patients are willing to trade 11% increase in recurrence rate within 
five years to receive NA instead of LF. This may be in line with findings from a recent 
randomized controlled trial. This trial reported similar patients satisfaction early after sur-
gery. However, at five years, almost 50% higher recurrence rate for NA (84%) compared 
to LF (32%) was reported, resulting in less patients satisfaction after five years in the NA 
group(2). However, van Rijssen et al. reported that patients with a contracture recurrence 
after NA would prefer NA again because of the better convalescence, which is not in line 
with our finding that patients find convalescence less important than recurrence rate(2).
Furthermore, contractures are more likely to be completely released after open 
surgery whereas some minimally invasive techniques lack the ability to release the 
joint contracture and/or lateral or spiral cord completely after one intervention(1, 3). 
We showed that this attribute was of high importance (28%). However, patients were 
willing to trade nine degrees of residual contracture for receiving NA instead of LF. In 
addition, they were willing to trade two degrees of residual contracture for receiving 
collagenase instead of LF, indicating that patients are willing to trade joint contracture 
for a less invasive technique.
In conclusion, lately, minimally invasive interventions for Dupuytren’s contracture 
have received increased attention because of their rapid convalescence and lower 
complication risk(1-3). However, this study shows patients find low recurrence rates and 
complete contracture correction the most important attributes when selecting a specific 
treatment. Convalescence, which is often mentioned as an important advantage of 
minimal invasive techniques, was found to be less important for treatment selection in 
our study(1, 7). This study may give the surgeon awareness of the patients’ preferences 
towards certain treatment attributes. They can use this information when consulting 
patients by focussing more on the most relevant attributes. In that way the surgeon 
and patient can decide together which treatment is best for that specific patient, by a 
shared-decision making.
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AbStRAct
Dupuytren’s and Ledderhose disease can be a cumbersome condition in patients with 
a severe diathesis with a very early onset. Two brothers are described with a reversed 
radial forearm flap on both hands and two upper lateral arm flaps on both feet with a 
long-term follow-up ranging from 14 to 25 years. They had multiple procedures of both 
hands before the flaps were considered.
No recurrence occurred under the flap. In very severe diathesis flaps should be 
considered in an earlier phase to prevent multiple procedures and early recurrence.
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IntRoDuctIon
Patients with a severe diathesis in Dupuytren’s Disease (DD) are known to have a poor 
surgical outcome after long-term follow-up with a recurrence rate of the disease ranging 
form 12% to 47% after dermofasciectomy(1,2). All depends of course on the definition 
of recurrence. Furthermore, most authors report no recurrent disease under the full 
thickness graft(3, 4). In addition, recurrent surgeries lead to high complication rates and 
social burden. Also the financial implications for society are high(5).
In search for less recurrence different kind of free flaps have been described as alter-
native treatment for severe DD cases(6, 7). However, no long-term follow-up has been 
reported following this extensive surgery surgery.
The aim of this report is to describe the long-term follow-up in two brothers with a 
severe diathesis following flap surgery for both hands and feet.
PAtIEntS
case 1
In 1978 a 30-year-old Caucasian male with a history of DD was referred to our hospital. 
In the following eight years twelve faciectomies combined with full thickness skin grafts 
(FTG) were performed on his right hand, left hand and left foot. He is a smoker and 
consumes four units of alcohol per day.
In 1986 the severity of his diathesis and the frequent recurrence of the disease 
prompted us to perform a reversed radial forearm flap (Rev. RFF), to cover the palm and 
the proximal phalanges of all fingers of the left hand excluding the thumb (Figure 1).
In 1991 his right hand was also operated with a Rev. RFF. In 1988 and 1996 both 
feet were operated with a free vascularised upper lateral arm flap (ULAF) following 
excision of painful large nodules impeding normal gait (Figure 3). Additional surgeries 
over the years were for an arthrodesis of the PIP joint of the fifth finger due to a painful 
degenerative arthritis, to resolve the residual syndactylies of both hands following flap 
surgery and to bury a pre-existent painful neuroma in the palm of the right hand.
In 2010, 24-years after surgery of the left hand and nearly 20 years after surgery of the 
right hand, no recurrent DD tissue has been noted under the flaps. The feet, respectively 
15 and 22 years postoperatively, have been free of recurrence since the initial free flap.
case 2
In 1986 a 37-year-old Caucasian male, brother of case one, was operated on both 
hands by using a Rev. RFF, after an extensive history of recurrent surgeries (over 30 for 
both hands and two for both feet) for DD since 1974 (Figure 2). He consumed 5-8 units 
of alcohol per day and had no history of smoking. The residual syndactylies of both 
hands following flap surgery were resolved in 1988 and in 1990.
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Between 1986 and 1990 two fasciectomies with FTG were performed on the first 
web space of his left hand and on his right foot outside the area of the flap. Arthrodesis 
of his DIP joint from his fifth finger of his left hand was performed in 1994, due to a 
painful hyperextension.
The right foot was operated with a free vascularised ULAF in 1997, with a com-
plicated postoperative recovery due to systemic co-morbidity, i.e. heart failure and 
jaundice. The flap survived. The left foot was therefore not operated (Figure 3).
After 25 years, the patient had no recurrence of DD tissue under the Rev. RFF, but he 
did suffer from extensions at the sides of the flaps. Fourteen years postoperative the right 
foot has been free of recurrence since the initial free flap. He still suffers from painful 
noduli in his left foot.
A B
DC
figure 1: This figure 
shows the preoperative 
(A) and peroperative (B) 
photograph of the right 
hand of our first patient. 
At that time he was 43 
years old. Twenty years 
after surgery the patient 
is able to extent the fin-
gers (C) and to make a 
fist (D).
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mEtHoDS
In both patients extensive measurements were performed during regular follow-up. 
The passive range of motion (ROM), grip strength (Jamar), and sensibility (Semmes and 
Weinstein monofilaments) were measured. Furthermore the Disability for Arm Shoul-
der and Hand (DASH), Cold Intolerance Scale (CISS), VAS pain scale and a satisfaction 
questionnaire were completed by both patients.
RESultS
Both patients cannot fully extend the fingers. Flexion is possible except in the small 
finger of the right hand of the first patient and in the small finger of the left hand of the 
A B
DC
figure 2: This figure 
shows the preoperative 
(A) and peroperative (B) 
photograph of the right 
hand of our second pa-
tient. At that time he was 
37 years old. Twenty-five 
years after surgery the pa-
tient is able to extent the 
fingers (C) and to make a 
fist (D).
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second patient (Table 1, Figure 1 and Figure 2). Grip strength was diminished with on 
average 10 kg. compared to their age group (C1: 26.02 kg. right hand; 26.65 kg. left 
hand and C2: 32.22 kg. right hand; 32.06 kg. left hand)(8).
The first patient reports pain only when using his hands (VAS score 5 to 7.9 out of 
10). This pain is especially in his right hand. The second patient had no pain in his right 
hand, but does suffer from a constant pain of 2.2 out of 10 in his left hand. During daily 
activity this pain rises to 4.6 out of 10. The feet were not painful, except the left foot 
of the second patient which was not operated. Both brothers scored above 30 points 
on the CISS and the DASH score was 36 out of 100 for the first and 25 out of 100 for 
the second patient. They experience some difficulties in daily activity, but overall they 
are very satisfied with the outcome of the surgery (8.4 out of 10 and 8.7 out of 10 VAS 
scale) and would not hesitate to do it again. They advised to perform the surgery earlier 
in the course of the disease.
DIScuSSIon
Two patients with a severe diathesis of Dupuytren’s Disease (DD) are described, in 
which reversed radial forearm flaps (Rev. RFF) were used for both hands and free 
vascularised upper lateral arm flaps for the feet, as an ultimate treatment solution 
after multiple procedures. Their hand function is acceptable and the patients are very 
satisfied with the overall results following the flap surgery in both hands and feet. No 
recurrence developed under the flap since the use of the flaps and patient burden was 
reduced extensively. It should be noted that these patients have been operated multiple 
A B C
figure 3: The surgical course of the feet of both patients is shown. Not all photographs were available. 
Therefore we can only show preoperative (A) and peroperative (B) photographs of the second patient 
and the 22-year follow-up photograph (C) of the first patient.
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Long-term follow-up of flaps for extensive Dupuytren’s and Ledderhose disease in one family
times and therefore demonstrate pain, cold intolerance and disability regardless of the 
use of flaps. The pain already existed prior to flap surgery. In the first patient a neuroma 
was buried in the palm of the right hand.
Skin grafts have been reported to act as a local ‘fire-break’ to prevent recurrence. 
Extensive dermofasciectomy with FTG is therefore treatment of choice for patients with 
a severe diathesis(9-10). However, the recurrence rate of dermofasciectomy, after mean 
follow-up of 13 years, is reported to be up to 47%(2). Dermofasciectomy compared with 
fasciectomy even shows the same recurrence rates of 12% after 36 months(1).
In studies using free vascular flaps for soft tissue coverage after palm and digit defects 
DD patients are mentioned, although survival of the flap and not recurrence of DD 
was the outcome(6, 11). However, the circumflex scapular artery perforator flap has been 
described with good clinical outcome in one patient with a one-year- follow-up(7).
Any large flap is an aggressive but alternative treatment for patients with severe DD; 
we used the Rev. RFF for this purpose. In very severe diathesis of DD’s with an early on-
set (3rd to 4th decade) we offer this kind of extensive surgery to these patients. However, 
nearly all patients decline this type of surgery in a very early stage. Only after multiple 
corrections the need for a different treatment is recognised. We have performed four 
more flaps to the hand for severe diathesis but with far less long-term follow-up when 
compared to the patients described. All these patients have not demonstrated recur-
rence under the flap until now. To reduce the patient burden and to lower costs it can 
be a good option to consider large flaps covering the palm of the hand and proximal 
fingers earlier.
case 1 case 2
Digit: 1 2 3 4 5 1 2 3 4 5
Extension / Flexion Extension / Flexion
Right 
hand
MP 0° / 
38°
−17° / 
90°
0° / 
53°
−18° / 
74°
−5° / 
70°
−3° / 
37°
6° / 
102°
−10° / 
96°
−11° / 
90°
−13° / 
94°
PIP −18° / 
54°
34° / 
99°
10° / 
97°
5° / 
94°
45° / 
45°
−12° / 
71°
40° / 
98°
13° / 
100°
6° / 
84°
20° / 
86°
DIP −23° / 
47°
−20° / 
31°
−5° / 
43°
−12° / 
10°
−1° / 
54°
0° / 0° −15° 
/ 4°
20° / 
38°
Left 
hand
MP −12° / 
42°
−18° / 
78°
−13° / 
90°
−10° / 
88°
−13 / 
87°
−5° / 
48°
2° / 
86°
8° / 
87°
45° / 
97°
30° / 
88°
PIP −12° / 
47°
5° / 
90°
4° / 
90°
32° / 
102°
17° / 
90°
−25° / 
56°
25° / 
83°
23° / 
86°
26° / 
64°
28° / 
36°
DIP −27° / 
38°
−10° / 
22°
−14 / 
10°
−7° / 
32°
3° / 
32°
−17° / 
24°
5° / 7° 45° / 
45°
table 1: This table shows the passive extension and passive flexion of the fingers of both hands of both 
patients. Both patients can extent and flex the fingers. Our second patient received an arthrodesis for 
his PIP5 of the left hand.
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AbStRAct
Background: Surgical resection of Dupuytren’s contracture is fraught with morbidity 
and prolonged recovery. This paper introduces a novel minimally invasive alternative 
for Dupuytren’s Disease and its outcome.
Methods: The procedure consists of an extensive percutaneous aponeurotomy that 
completely disintegrates the cord and separates it from the dermis. Subsequently the 
resultant loosened structure is grafted with autologous lipoaspirate. After one week 
of post-operative extension splinting patients are allowed normal hand use and are 
advised to use night splints for three to six months. We treated and report on our experi-
ence with 91 patients (99 hands) operated in Miami and Rotterdam; from 50 patients 
we report on goniometry (average follow-up of 44 weeks).
Results: The contracture from the PIP joint improved significantly from 61 degrees to 
27 degrees and the MP joint from 37 degrees to −5 degrees. Ninety-four percent of 
patients returned to normal use of the hand within two to four weeks and 95% were 
very satisfied with the result. No new scars were added and a supple palmar fat pad 
was mostly restored. Complications were one digital nerve injury; one post operative 
wound infection and four patients with CRPS.
Conclusion: This new invasive technique shortens recovery time, adds to the deficient 
subcutaneous fat and leads to scarless supple skin. By its ability to treat multiple rays, 
it addresses the pathology in the entire hand. The procedure is safe and effective, espe-
cially for the primary cases. Currently comparative prospective randomized studies are 
in process to fully determine its role in treatment of Dupuytren’s contracture.
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IntRoDuctIon
Dupuytren’s disease (DD) is a benign, progressive, fibroproliferative, chronic disorder 
that results in abnormal scar-like tissue in the palmar fascia of the hand. Extension to 
the digits causes progressive digital flexion contractures. Treatment of DD is mainly 
surgical. Limited fasciectomy and limited dermofasciectomy are the techniques mostly 
used(1). Although excisional surgery seems to be the standard treatment, the procedure 
is fraught with a significant rate of complications(1). However, the greatest drawback of 
surgery is the associated morbidity and the time required until return to normal use of 
the hand. This need for less morbidity and shorter recovery time opened the door for 
less invasive treatment alternatives(2, 3).
Collagenase injections are a less invasive treatment option that can significantly 
reduce flexion contractures. The drawback seems to be the inflammatory reaction 
caused by collagenase and its potential harm to tendons and surrounding tissues. The 
results are promising, but the treatment is not widely available yet, no long-term follow-
up data are available and a comparison to other treatment alternatives is lacking(4, 5). 
Radiotherapy is another less-invasive treatment alternative. However, radiotherapy has 
only been administered for early stage DD(6).
Percutaneous release of contracted cords by needle aponeurotomy only is also less 
invasive and is recognized to promote fast postoperative recovery(7, 8). However, a 65% 
recurrence rate after 32 months has been reported using the standard procedure which 
consists of a few full thickness cord cuts with a needle(8).
Despite its great appeal to patients, our experience with percutaneous aponeurotomy 
was also disappointing due to the rapid recurrence of the contracture. Having found 
that fat grafting is beneficial in softening scars in other clinical conditions, one of the 
co-authors (RKK) decided to combine fat grafting with a novel minimally invasive per-
cutaneous release technique that is permissive to fat grafting. In this study, we describe 
this new surgical method of extensive percutaneous aponeurotomy with lipofilling 
(PALF) and report our first results from a cohort of 50 patients.
mEtHoDS
A Surgical technique
Fat harvesting
Prior to operating on the hand, the abdomen and ipsilateral flank are prepped and 
draped. Through two to three puncture sites with a 14G hypodermic needle we diffusely 
inject in the subcutaneous fat 500 – 600ml of a tumescent solution containing 50ml of 
2% Lidocaine and 1ml of 1:1000 Epinephrine per litre of physiologic solution. We then 
harvest the fat by manual liposuction using a 12G (2.7mm) 12 (1x2mm) holes 25cm 
long cannula connected to a syringe pulling a steady 300 mmHg vacuum suction. To 
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separate the graft from the serum and tumescent solution, the collected lipoaspirate is 
then allowed to sediment on the side table while the extensive percutaneous aponeu-
rotomy is performed.
Extensive Percutaneous Aponeurotomy
Under regional or general anesthesia, the extremity is tightly exsanguinated. This col-
lapses the vessels into cord-like structures and minimizes the damage from the needle. 
The digits are placed under maximal extension tension using a firm lead-hand retractor 
(Figure 1). Then, progressing in an orderly fashion from proximal to distal, multiple 
palmar puncture wounds are made with a needle-like sharp-tipped bevelled piercing 
instrument. Working along a wide area around the contracture, the palpable cords 
under tension are progressively and extensively severed through slight transverse oscil-
lations at each puncture point. Tension is maintained by constantly extending the digits 
as the contracture progressively gives way. Residual restricting bands are localized 
by palpation and addressed in the same fashion. In order to maintain tension on the 
figure 1: Peroperative photographs showing the peroperative release of the cord and lipografting of the 
same patient. Note the multiple puncture sites.
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released area, we carefully avoid skipping to a distal site until the proximal site is fully 
released and soft (Figure 1).
The differential cutting effect provided by the tension on the cords is crucial. Tight 
constricting bands are most susceptible to be cut and torn by the small nicks, while 
the relatively looser neurovascular structures are spared. Since the internal collagen 
fibrous structure of the cord is a spiral-like weave, we only need to sever the fibres 
during their superficial course to inflict attrition damage to the entire weave and break 
it apart (Figure 2).
The other important safety aspect is the depth of penetration that never exceeds 3mm 
proximal to the transverse palmar crease and 2mm in the distal palm and digits since the 
digital nerve can be located dangerously superficial by a spiral cord. Depending upon 
the severity of the contracture and the size and firmness of the nodules this process often 
requires up to 50 puncture wounds per digital ray. Skin wrinkles and pits are released by 
severing the dermal attachments of the cord with a windshield wiper motion of the “L” 
shaped cutting device (Dupuytome™; Marina Medical, Sunrise, Florida, 33326 USA).
figure 2: Schematic representation of the intervention. Under maximal tension the cord (red) is released 
from proximal to distal with multiple needle nicks. The digital nerve is yellow. After total release of the 
cord a 3D space is created in which fat can be injected.
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The hand is ready for lipografting once the contracture is fully released, the skin fully 
supple and separated from the cord, and the nodules are completely chopped and soft.
Lipografting
We inject the released and loosened fibrous structure with the supernatant of the 
lipoaspirate harvested from the abdomen or flanks. Through two to three needle entry 
sites in the palm and the digit, using a spatulated single side hole blunt tip 14G can-
nula, the lipoaspirate graft is injected in multiple planes, while retracting the cannula 
along fanning tunnels. We usually inject a total of 10ml per digital ray and expect some 
of it to escape through the needle release sites. The very dilute injectate provides a 
margin of safety against over grafting. The tumescent effect of loose fat injection slightly 
balloons up the palmar skin to reveal any residual tethering dermal band that are then 
further released by the windshield wiper effect of the sharp tipped Dupuytome™.
postoperative care
A conforming dressing over the palmar skin that incorporates a plaster extension splint 
is kept for five to seven days. After removal of the intra-operative dressing, the patient 
is allowed to return to his normal activities and advised to use a night extension splint 
for up to 20 weeks.
b Patient population
Over a 32-month period, extensive percutaneous aponeurotomy combined with li-
pofilling was performed on a total of 91 patients and 99 hands eight patients were 
treated on both hands 69 males and 22 females) in Miami or Rotterdam. Patients were 
eligible for this procedure when the table-top-test was positive, regardless of whether 
the contraction was in the MP or PIP joint. Thirteen patients suffered from recurrent DD 
and had previously been operated using a fasciectomy. A medical ethical approval was 
obtained for analysis of the clinical data used for this study (MEC-2010-283; Erasmus 
MC, Rotterdam, The Netherlands).
As a part of the clinical routine, goniometry data were collected (Rotterdam) and 
clinical pictures of the hands were taken (Rotterdam and Miami). From a total of 52 
patients, both preoperative and postoperative goniometry data of the MP-joint and PIP-
joint were recorded or could be measured from the clinical pictures(9-11). Reasons for 
incomplete goniometry data were the inability or unwillingness of patients to come for 
follow-up (many patients, especially in Florida, live abroad). Also a number of patients 
were deceased. Two of the 52 patients had a first web contracture and were left out 
the analysis. From the 50 patients, 15 had a MP-joint contracture, 11 had a MP-joint 
contracture, and 24 had both a PIP-joint and MP-joint contracture. The amount of con-
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tracture was transformed to the Tubiana grading system to establish the total amount of 
improvement per ray.
Complications, satisfaction with the operation, gain in hand function and amount of 
time to full recovery was scored and we asked patients if they would recommend the 
same procedure again.
Statistical analysis
For each patient, we evaluated the most severely affected finger joint in the treated 
hand. We performed a paired t-test on the range of motion to compare preoperative 
versus postoperative contracture of the PIP joint and the MP joint. A Wilcoxon sum rank 
test was performed on the Tubiana grading group distribution.
RESultS
Experiences during the operation
We were able to perform the procedure with a similar operating room time as for a 
fasciectomy. Operative time, including harvesting the grafts, was approximately 1 to 
1.5 hours, depending on the amount of rays treated and was therefore comparable to 
conventional open fasciectomy times in our institutions.
We typically treated the entire palm of the hand and all the affected digital rays. Intra-
operatively we achieved full MP-joint extension in all patients. Full PIP-joint extension 
was not always achieved as severe contractures were mostly combined with capsular 
contractures. The cord could always be fully released. There were no skin deficiencies 
in the primary cases, even in the most severe contractures. Only in two recurrent cases, 
the old scar ripped open during the release, requiring a small flap and a graft.
follow-up data
In the 50 patients from who complete data were available at a mean follow-up of 
44 weeks, we found a significant flexion contracture correction of the PIP joint from 
61 degrees to 27 degrees and the MP-joint from 37 degrees to −5 degrees (Table 1). 
When we selected the PIP-joint and MP-joints with a flexion contracture of 45 degrees 
or more, the PIP-joint improved significantly from 70 degrees to 29 degrees and the 
MP-joint improved significantly from 54 degrees to −4 degrees. Following surgery 88% 
patients obtained Tubiana stage 1 (Table 2).
From experience during follow-up at the out patients clinic, the most impressive 
finding was the restoration of a supple subcutaneous fat pad. The treated skin previ-
ously overlying the cords could be pinched off the deep fascia just like normal healthy 
palmar skin, which is rarely seen in the scarred hand following conventional limited 
fasciectomy (Figure 3).
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clinical experience: convalescence and complications
Our clinical experience was that except for four patients, in the total group of 91 pa-
tients, recovery and regained use of their hand for activities of daily living was acquired 
approximately one week after surgery. Return to either work or vocational activities 
was within two to four weeks. The four patients with a longer recovery time were all 
women with severe diathesis who had symptoms of CRPS such as swelling, diminished 
function and pain. Two of these patients had a history of CRPS in the other hand after 
open surgery for Dupuytren’s contracture and described their symptoms after the pres-
ent procedure as less severe. There were no tendon injuries. There was one digital nerve 
injury (1.1%) and one post-operative wound infection (1.1%). Both complications oc-
curred in previously operated hands. Except for one patient with wound infection, no 
delayed wound healing occurred.
Patient Satisfaction
Of the 91 patients 87 (95.6%) were very satisfied and would recommend the surgery to 
family and friends. All 13 patients who had previous open surgery preferred this new 
procedure over their previous experience. The procedure left no visible scar, and led to 
subjective improvement in the feel and softness of the entire hand.
tubiana grading: Extension deficit 
of three joints combined
Preoperative:
number of patients per group
Postoperative:
number of patients per group
1 0° - 45° 9 44
2 45° - 90° 26 6
3 90° - 135° 14 0
4 ≥135° 1 0
table 2: Distribution of the patients over the different Tubiana gradings. The Tubiana grading is defined 
based on the total extension deficit of the three finger joints combined. Postoperatively, almost all pa-
tients had a total extension deficit in the worst finger of less than 45˚ according to the Tubiana grading.
Preoperative 
(SD)
Postoperative 
(SD)
Improvement 
(%)
P-value
follow-up 
(weeks)
PIP-joint contracture (n = 39) 61.3° (24.5°) 26.7° (21.7°) 34.6° (56.4%) <0.001 43.8
MP-joint contracture (n = 35) 36.5° (18.9°) −5.1° (8.2°) 41.6° (114.0%) < 0.001 42.2
PIP-joint contracture ≥ 45° (n = 32) 69.8° (17.2°) 29.4° (21.3°) 40.3° (57.7%) <0.001 43.8
MP-joint contracture ≥ 45° (n = 15) 54.3° (8.9°) −3.6° (6.5°) 57.9° (106.6%) <0.001 44.3
table 1: Results of the 50 patients of whom goniometric data were available. Extension deficit is shown 
in degrees. The third column shows the improvement of extension in percentages. Follow-up is in weeks 
after surgery. Results are presented separately for patients with a relatively mild joint contracture (<45 
degrees) en more severe joint contractures (≥45 degrees)
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Three of the four patients with post-operative CRPS stated they would not choose this 
type of surgery again. Interestingly, the fourth will still recommend this same procedure 
to family and friends. Another patient was not satisfied, despite a positive outcome, 
because the operated other hand was straighter.
DIScuSSIon
The most striking result during extensive percutaneous aponeurotomy was the release of 
the skin and cord even in fully flexed fingers. Operating time of PALF was comparable 
to limited fasciectomy or dermofasciectomy. In our experience, the main gain of the 
minimally invasive technique is the short recovery time compared to the open surgical 
technique, especially if more rays are involved. However, a randomized controlled trial 
is needed to directly compare both techniques.
Open fasciectomy is the recognized standard treatment for Dupuytren’s contrac-
ture. The complication rate of 18 to 29%, the recurrence rate of 27 to 70% after five 
years and the inherently long recovery time of fasciectomy however, have fueled the 
emergence of less invasive techniques, such as the injection of collagenase(1, 10-12). A 
preoperative 2 weeks postoperative 1 year postoperative 
figure 3: Illustrations of a 63-year-old male patient with Dupuytrens contracture in the second ray. The 
palmar, lateral view and fist position are shown preoperative, two weeks postoperative and one year 
postoperative from left to right.
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recent randomized clinical trial (RCT) compared collagenase injections with a placebo. 
Patients received up to three direct injections thirty days apart, requiring an average 
of 56 days. At thirty days follow-up, MP-joint and PIP-joint contractures significantly 
improved. Two tendon ruptures and one case of CRPS were reported(13). While the 
procedure seems to have merit, the treatment is costly and long-term follow-up data is 
lacking. Collagenase has not been compared directly to a non-placebo alternative and 
is presently limited to one affected joint at a time.
Needle aponeurotomy (NA) is another minimally invasive technique(8, 14, 15). In a 
RCT comparing needle aponeurotomy versus limited fasciectomy, a 75% reduction in 
MP-joint extension deficit and a 33% reduction in extension deficit for the PIP-joint 
at six weeks follow-up was reported in the needle aponeurotomy group(7). The minor 
complication rate was 50% in the NA patients versus 30% after open surgery; major 
complication rates were 0% and 5%. This is in line with reported complications of skin 
rupture, infection, digital nerve transaction, tendon ruptures and even the development 
of a false aneurysm(16, 17). At the 2010 European Association of Plastic Surgeons meeting 
in Manchester, van Rijssen et al. reported an 85% recurrence rate at 5-year follow-up 
in the needle aponeurotomy group(18).
The needle technique in our new procedure was refined compared with conventional 
NA by using multiple superficial nicks in the pathological region. The essence of the 
needle technique is not to use the needle too deep, especially more distally. To ensure 
this, the bevel of the needle is never completely out of sight. There is no attempt to 
transect the cord with one needle cut; this would take the needle to deep, which could 
be damaging other tissues than the diseased fascia. There is no limit for the amount 
of rays that are treated; even nodules in other rays can be treated in the same session.
Fat grafting is a critical component of this new procedure. One reason for this is 
to provide supple skin by supplying fat. Dupuytren’s contracture is associated with 
subdermal fat deficiency as the pathological fibrosis displaces the fat to adhere to the 
dermis. This new procedure releases the fibrous scar from the dermis and restores a 
subcutaneous fat layer over the affected area. A second reason is that interposed grafts 
are reported to prevent the recurrence of Dupuytren’s contracture(19). In our procedure, 
interposed fat grafts in the space created by the released fibers might have a similar 
beneficial effect. Furthermore, since these fat grafts come from the abdomen, a region 
of the body not prone to contracture, it is likely that they will not have the same ten-
dency to convert into fibrous bands. A third reason is that fat grafting is known to be 
a rich source of stem cells with regenerative potential(20). Fat grafting has been shown 
to improve the quality of the skin and to be beneficial in the treatment of radiation 
damage, chronic ulceration and scar tissue around breast capsular contractures(20, 21). 
Since the pathophysiology of Dupuytren’s contracture is akin to that of a scar, it would 
seem logical that fat grafts would also be beneficial in this disease setting.
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PALF notably differs from NA, an office procedure done under local dermal anes-
thesia. NA specifically avoids lidocaine infiltration of the neurovascular bundles such 
that an attentive patient with sensate nerves is the safeguard against nerve injury during 
deep full thickness needle transections of the cord. In contrast, PALF is performed on a 
prepped and draped hand in the operating theatre under regional block with a tourni-
quet ischemia and sedation. Safety from nerve injury is inherent in the PALF design as a 
result of the difference in stiffness of the stretched cords and the nerves (see Methods).
Drawbacks of our new technique could be accidental damage of surrounding nerves, 
digital arteries and tendons. In our combined series treated in Rotterdam and Miami 
no tendon lesions were encountered and only one infection. One nerve was injured 
in a recurrent diseased finger and in four cases a CRPS evolved. Two of these patients 
already had a CRPS in the contralateral hand following earlier open surgery. Another 
drawback of PALF is that the arthrogenic part of the flexion contracture cannot be 
corrected. With PALF only the dermatofibrous contractures can be released, which 
may leave a residual capsulogenic contracture. Many experienced surgeons, however, 
are often also not inclined to release a capsulogenic contracture during open surgery 
because of the potential stiffness of the PIP-joint or reactive recurrence of the PIP-
contracture.
Our clinical study has of course limitations. We have treated 91 patients and can re-
port on goniometry data from only 50 patients. As we do not have long-term follow-up 
results recurrence rates do not seem appropriate yet. In addition, our patients may not 
reflect the normal Dupuytren population since the Erasmus University Medical Center 
is a referral center with 39% of its patients having a severe diathesis. Another limitation 
was that an independent researcher measured the range of motion and therefore there 
was no blinding.
Comparing the PALF-results with the NA-results in the literature is difficult as we 
selected the worst finger per patient instead of adding all rays regardless of number of 
patients. Furthermore, the number of patients differs, follow-up time differs and the per-
centage of patients with severe diathesis is high in our series. It seems, however, that our 
data concerning the MP-joint are favorable, as improvement is 100% compared to 79% 
and 75% in NA treated patients(7, 16). For the PIP joint our contractures were significantly 
more severe (preoperative mean 61.3˚ compared to 37˚)(16). Improvement of the PIP-joint 
was 56% in our study compared to 65% in Foucher’s and 33% in van Rijssen’s article(7, 15).
Based on these preliminary results, extensive percutaneous needle aponeurotomy 
with subdermal fat grafting has a great potential. Patients with DD mostly need multiple 
surgeries during their life, so a less invasive surgical method should be a treatment of 
first choice. To achieve a higher level of scientific evidence, we started a single blind 
multicenter RCT in Rotterdam to compare the new minimal invasive surgery with the 
surgical limited or (dermo)fasciectomy.
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AbStRAct
Background: As an alternative to the needle aponeurotomy (NA) release and the limited 
fasciotomy (LF) treatment of Dupuytren contracture, we introduced the extensive percu-
taneous aponeurotomy and lipofilling (PALF) procedure. In our previous retrospective 
study, we reported that contractures significantly improved and most patients returned 
to normal use of the hand within two to four weeks. To establish the safety and efficacy 
of PALF, we compared it to the standard LF in a single-blinded multicenter, prospective, 
controlled, randomized trial.
Methods: Patients with a primary Dupuytren’s contracture were randomly assigned to 
the LF-group or the PALF-group. Patients were measured at baseline and at two weeks, 
three weeks, six months and one year post-operatively. Primary outcome of the trial 
was contracture correction and convalescence time. Groups were compared using a 
mixed models approach.
Results: Eighty patients were included in this study and randomized to PALF or LF. In 
both groups, almost full MP-joint contracture correction was obtained while for the PIP-
joint some residual contracture remained. In addition, the patients in the PALF-group 
returned significantly earlier to their normal daily activity. At one-year post surgery, no 
significant differences in recurrence rate and hand function were present. However, LF 
seems to have a higher incidence of permanent complications than PALF.
Conclusion: PALF demonstrates a significantly shorter convalescence; similar operative 
contracture correction; lower incidence of long-term complications and no significant 
difference regarding one-year postoperative results when compared to LF. PALF is there-
fore a valuable minimally invasive alternative to the treatment of Dupuytren’s disease.
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IntRoDuctIon
Dupuytren’s disease (DD) is a benign fibroproliferative disorder that causes progressive 
digital flexion contractures(1). The most common treatment of DD is limited fasciectomy 
(LF), an invasive procedure that excises the diseased fascia and requires flaps or grafts 
to reconstruct the released contracture. While LF has well-accepted low long-term 
recurrence, it has a relatively high complication rate due to the extensive dissection 
required and the postoperative return to normal hand function for daily activities (con-
valescence) is typically quite prolonged(1-3).
Percutaneous release of the fibrotic cord, also referred to as needle aponeurotomy 
(NA), is a less invasive alternative technique that promotes faster recovery(3-5). A trial 
comparing NA with LF reported lower complication rates, faster recovery, but lesser 
contracture correction after six weeks(3). Furthermore, five years postoperatively, NA 
had a significantly higher recurrence (85%) than LF (32%)(6).
To improve on NA, we developed another minimally invasive procedure consisting of 
an extensive percutaneous aponeurotomy and lipofilling (PALF)(7). This technique com-
pletely disintegrates the cord, separates it from the dermis, and turns it into a loosened 
recipient scaffold for grafting with autologous lipoaspirate. Lipofilling has many ben-
efits: First, it reduces the density and cell-to-cell contact of contractile myofibroblasts(8). 
Second, adipose-derived stem cells (ADSC) in the lipoaspirate were found to reduce 
the recruitment of additional myofibroblasts by inhibiting their proliferation(8). Third, 
fat grafts may also function as interposed tissue grafts while interposed tissues, such as 
cellulose, are reported to prevent the recurrence of Dupuytren’s contracture(9). Fourth, 
Dupuytren’s contracture is associated with subdermal fat deficiency as the pathological 
fibrosis displaces the fat to adhere to the dermis; therefore, fat grafting may provide 
supple padding to this diseased region(10, 11).
In our recent retrospective review of 50 patients treated with PALF, we found a sig-
nificant contracture improvement preserved at one year, while 94% of patients returned 
to normal use of the hand within 2 to 4 weeks, and 95% were very satisfied with the 
result(7). In order to compare this novel technique with established alternative treatment 
options, we performed a single-blinded, multicenter prospective, controlled random-
ized trial comparing it with LF. The primary outcome measures were convalescence 
and contracture correction.
mEtHoDS
Study population
Between the 24th of February 2009 and the 1st of October 2011, we enrolled at 
Erasmus MC and Sint Franciscus Gasthuis (SFG) 80 patients with primary Dupuytren’s 
contracture and a flexion contracture of at least 20° at the MP-joint or at least 30° at 
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the PIP-joint, or both. Patients were excluded if the affected finger had a prior interven-
tion, or if anticoagulants could not be stopped. To standardize patient instructions, a 
short movie explained the trial before patients consulted with the researcher and their 
surgeon. All included patients gave informed consent. The Medical Ethical Commit-
tee of the Erasmus MC in Rotterdam (MEC-2008-264) approved this study and it was 
registered at the Dutch Trial Register in March 2009 (NTR1692).
Randomization
Patients were randomly assigned to the LF-group or the PALF-group through sealed 
envelopes. A computer random number generator selected random-permuted blocks 
of ten patients. The patients received a trial number and the correspondingly numbered 
envelope was given to them, with either a ‘PALF’ or ‘LF’ note inside. Bilaterally affected 
patients who requested surgery for their contralateral hand served as their own control 
with the contralateral hand given the opposite treatment.
Surgical techniques
Four surgeons (S.H., C.N, E.W. and X.S.) performed both alternative procedures at 
both centers. Patients were operated following complete exsanguination, tourniquet 
ischemia, and under general or regional anesthesia with or without sedation. In both 
groups, patients received hand therapy and instructions to wear an extension splint at 
night for six months.
Extensive Percutaneous Aponeurotomy and Lipofilling (PALF): The technique is previ-
ously described in Clinics of Plastic Surgery(12). Briefly, the digital contractures are placed 
under maximal tension in extension using a firm hand retractor. Then, progressing in 
an orderly fashion from proximal to distal along the palpable contracture, multiple 
palmar puncture wounds are made with a 19-gauge needle. Tension is maintained by 
constantly extending the digits as the contracture progressively gives way. Skin wrinkles 
and pits are released by severing the dermal attachments of the cord with a windshield 
wiper motion of an “L” shaped needle. The hand is ready for lipografting once the con-
tracture is fully released, the skin fully ironed out and separated from the cord, and the 
nodules are completely ‘chopped’ and soft. We then inject 8-10ml of non-centrifuged, 
simply sedimented lipoaspirate per digital ray and expect some of it to escape through 
the needle release sites. A conforming dressing over the palmar skin that incorporates a 
plaster extension splint is kept for five to seven days (Figure 1).
Limited fasciectomy (LF): A longitudinal or Brunner incision was made into the palm 
overlying the affected area and extended into the finger. A Z-plasty was performed to 
lengthen the incision when a longitudinal incision was used. In case of a Brunner inci-
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figure 1: PALF technique illustration: preoperative photo of a patient with a Dupuytren contracture of 
the fifth digit on the right hand (A). Making of multiple nicks from proximal to distal with a 19-gauge 
needle (B and D). Releasing dermal attachments of the cord with a windshield wiper motion of an “L” 
shaped needle (C, E and F). Placement of the digital contractures under maximal tension in extension, 
using a firm hand retractor during the whole operation (G). The hand is ready for lipografting once the 
contracture is fully released (H). Injection of 8-10 ml. of non-centrifuged, simply sedimented lipoaspi-
rate per digital ray (I). Plaster extension splinting, kept on for five to seven days (J).
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sion the skin was closed in a V to Y fashion. First the diseased fascia was dissected off 
the skin. Then, the diseased fascia was removed off the deeper structures as adequately 
as possible. Neurovascular bundles and the flexor tendon sheaths were identified and 
protected. The skin was closed primarily using interrupted sutures. If the skin was af-
fected too much it was removed and a full thickness graft was used to close the wound. 
The hands were splinted for five to seven days and the sutures were removed after 14 
days.
measurements
Patients were measured at baseline and at two weeks, three weeks, six months and one 
year post-operatively. Trained examiners from the clinical movement analysis lab of the 
department of Rehabilitation Medicine collected all baseline and outcome measures. 
To blind the examiners to the treatment allocation, patients wore blue non-latex gloves 
during the measurements and were instructed not to discuss their treatment with the 
examiners. Patients, surgeons, hand therapists, and the trial coordinator (HJK) were not 
blinded for group allocation.
Primary outcome measures were contracture correction and convalescence period. 
To determine contracture correction and recurrence rate, we measured the passive 
extension deficit of the MP, PIP and DIP joints at all time points. Convalescence was 
estimated as the ability to flex the MP, PIP and DIP joints based on goniometric mea-
sures and based on a diary questionnaire asking about the number of days till return to 
all normal daily activities.
Secondary outcome measures were patient-reported hand function, pain, recurrence 
rates, patient satisfaction, and complication rates. To assess hand function, we asked the 
patients to fill in the Dutch translation of the Disabilities of the Arm, Shoulder and Hand 
(DASH)(13). Pain during activity was measured by using a visual analogue scale (VAS)(14). 
Recurrence rate was based on a recently published consensus definition, describing a 
recurrence as an increase in joint contracture in any treated joint of at least 20 degrees 
at one year post-treatment compared to six weeks post-treatment(15). However, since at 
the time of study design, this definition was not yet available, we used our three weeks 
measurements instead of 6 weeks.
Patient-satisfaction was measured by a questionnaire consisting of seven questions 
(see Table 2). To determine the complication rate, after surgery, a plastic surgeon in-
spected the wounds for infections and healing complications and for the presence of a 
complex regional pain syndrome type 1 (CRPS-1; scored using the Bruell classification) 
or other complications. In addition, any complication during surgery, such as nerve or 
arterial damage, was scored.
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baseline characteristics
PALF LF p-value
Characteristics
Mean age + SD (years) 63 (9) 63 (8) 0.951
Sex
Male
Female
37
7
25
7
0.508
Most severe affected finger
 dig 1
 dig 2
 dig 3
 dig 4
 dig 5
0
1
2
10
31
0
0
0
8
24
0.517
Number of treated fingers
 1
 2
 3
 4
 5
15
9
5
0
1
14
6
0
0
0
0.185
Family history with DD
Yes
No
25
19
16
16
0.556
Both hands affected
Yes
No
41
3
28
4
0.398
Ectopic disease
Yes (Ledderhose/Peyronie)
No
13
31
4
28
0.078
Alcohol a day (units) 2.2 (1.7) 2.3 (2.2) 0.827
Smoking
Yes
No
Former
8
10
26
12
7
13
0.145
Diabetes Mellitus
Yes
No
4
40
5
27
0.384
Heavy manual labor
Yes
No
12
32
11
21
0.605
Median DASH score (preoperative) 10 10 0.816
Median VAS score for pain (preoperative) 0.3 0.6 0.669
Mean exsanguination time + SD (minutes) 48 (17) 46 (19) 0.615
table 1: Baseline characteristics of both groups. Shown are means (SD) and numbers of patients and the 
p-value of the difference between groups.
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Sample size estimation
For the power analysis, we assumed that a 10 degrees difference in contracture is a 
clinically relevant difference that should be detected with this method. Based on an al-
pha of 0.05, an SD of 15 degrees, a beta of 0.80 and based on a two-sided independent 
sample t-test, we needed 37 patients per arm(7).
Statistical analysis
Patient demographics and outcome variables at baseline were compared between 
treatment groups to ensure comparability of the groups and described using mean and 
standard deviation for continuous variables and percentages for categorical variables. 
Continuous variables were compared with use of the Student’s t-test, whereas differ-
ences in categorical variables were compared using the Pearson chi-squared test.
To avoid dependency in outcome measures when multiple fingers and joints are 
analyzed within the same patients, we selected only the most affected finger at the pre-
operative measurement for further analysis based on the sum of the extension deficits 
in degrees from the MP-joint and PIP-joint.
All measurements repeated over time (goniometry, DASH and VAS) were assessed 
using a mixed models approach. The Mann-Whitney-U test was used for comparing 
the days needing to return to normal daily activities and the satisfaction questionnaire. 
baseline measures
     & treatment
1 year post-treatment
6 months post-treatment
3 weeks post-treatment
2 weeks post-treatment
waitinglist
80 patients (80 hands)
1 patient excluded
(1 hand)
10 patients exlcluded
(10 hands)
PALF
 40 patients (40 hands)
randomization
5 patients also 
received PALF for 
controlateral hand
LF
 40 patients (40 hands)
 39 patients 
(44 hands)
2 patients also 
received LF  for 
controlateral hand
 30 patients 
(32 hands)
 28 patients 
(31 hands)
 27 patients 
(30 hands)
 28 patients 
(31 hands)
 27 patients 
(30 hands)
 37 patients 
(41 hands)
 38 patients 
(43 hands)
 39 patients 
(44 hands)
 37 patients 
(42 hands)
figure 2: Flow diagram
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A Chi-square test was used for comparing the difference in recurrence rates and com-
plication rates and the last two questions of the satisfaction questionnaire. All analyses 
were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL).
RESultS
Patients
Eighty patients with 88 treated hands were included in this study and randomized to PALF 
or LF treatment. One patient from the PALF-group and 10 patients from the LF-group were 
excluded before surgery while still on the waiting list (Figure 2), largely due to its length in 
both centers (mean 22±17 weeks). The reason for exclusion before surgery for the PALF 
patient was reported fear of surgery in general. He did not receive any other treatment 
in our center. The reasons for exclusion before surgery in the LF-group were waiting 
list length (three), other medical problems (two cancer, one intermittent claudication), 
unhappy with randomization into LF (two), decision not to be treated anymore (one), and 
family circumstances (two). There were no significant differences in the characteristics 
between those patients who were excluded from both treatment groups.
In total, five patients initially treated with LF received PALF on the contralateral hand 
and three initially treated with PALF had LF on their contralateral hand, resulting in a 
total of 44 PALF treated and 32 LF treated hands. Loss to follow-up was minimal and 
was mainly due to practical reasons for missing a specific measurement point. At six 
months, follow-up in the PALF-group was 100% while in the LF-group one patient 
did not return for assessment for personal reasons. At 12 months, two patients in both 
groups did not return for measurements (Figure 2).
Overall, patients were predominantly males, the fourth and fifth digit were most 
affected, and many had ectopic disease (Table 1). Baseline characteristics were not 
significantly different between groups.
contracture correction
Figure 3 and Figure 4 show the goniometric measurements at a different time of follow-
up. Significant contracture correction was obtained in both groups. Comparing groups, 
the overall interaction effect between time and group was not statistically significant 
(p=0.35), indicating a similar change in both groups over time. Evaluating affected PIP-
joints and MP-joints separately, we found that treated MP-contractures obtained almost 
full contracture correction and remained at this level at all follow-up times in both 
groups; for the PIP-contractures some residual contracture remained in both groups 
and contracture increased again later after surgery. Again, no significant interaction 
effects between treatment and time were found, indicating that the curves were not 
significantly different between groups.
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convalescence
Total flexion movement was generally lowest at two weeks after surgery, indicating a 
loss in the ability to make a full fist (Figure 5). The initial values, representing normal 
ability to make a fist, were regained again after surgery in both groups. However, 
we found a significantly improved ability to make a fist early after surgery with PALF 
(p=0.008).
In line with the better total flexion movement early after surgery with the PALF, we 
found that they returned significantly earlier to their normal daily activity: median nine 
days for PALF compared to a median of 19 days for LF-group (p=0.001).
Recurrence
At one year postoperative, 15 of the 85 (18%) PALF treated joints had some recurrence 
compared to five of the 58 (9%) LF treated joints. This was not a statistically significant 
difference (p=0.107). This finding is in line with the earlier reported non-significant 
difference in the goniometry curves of both groups of the TPED and the PIP-joint and 
MP-joint.
Patient-reported outcomes
Pain scores before and after surgery where generally low in both groups and we found no 
interaction effect of time and group for pain (p=0.593). Hand function, as measured with 
the Quick DASH, significantly improved over time in both groups (p=0.007). However, 
mean DASH scores were not significantly different (p=0.315) at baseline between treat-
questions
6 months 1 year
PAlf lf p-value PAlf lf p-value
Are you satisfied with the overall 
treatment outcome of the operation?
8.8 8.8 0.940 7.8 9.4
0.006*
Do the results of the operation meet 
your expectations?
8.9 8.6 0.742 7.8 9.4
0.007*
Are you satisfied with the contracture 
correction?
7.9 8.6 0.220 7.4 9.1
0.011*
Are you satisfied with the function of 
your hand?
8.9 8.6 0.460 8.7 9.3
0.125
Are you satisfied with the cosmetic 
appearance of the operated hand?
9.0 9.0 0.825 9.0 8.8
0.142
yes no yes no yes no yes no
Would you choose the same operation? 88% 12% 81% 19% 0.335 81% 19% 80% 20% 0.920
Would you recommend the same 
operation to your family and friends?
90% 10% 87% 13% 0.598 80% 20% 80% 20% 0.920
table 1: Patient satisfaction at six months and one year after surgery. For the satisfaction questions, 
medians are shown. For the questions on whether patients would choose the same operation of recom-
mend the operation, percentages of patients are shown.
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ment groups (Figure 6). At six months postoperative, there was no significant difference in 
any of the satisfaction questions (see Table 2). At one year after surgery, LF-treated patients 
were significantly more satisfied on the overall treatment outcome, contracture correc-
tion, and whether treatment expectations were met. However, no significance difference 
was found in percentages of patients who wanted to receive the same operation again 
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figure 3: Contracture correction (MP-joint and PIP-joint): goniometric outcomes measured preopera-
tively and at 2 weeks, 3 weeks, 6 months and one-year after surgery. These figures indicate the amount 
of PIP joint contracture (A) and MP joint contracture (B) at the different time points.
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and who wanted to recommend their type surgery to family and friends. Also all other 
satisfaction-related questions were similar between groups (Table 2).
complications
The overall complication rate was not significantly different among the groups (p=0.402). 
Two patients (5%) within the PALF-group developed severe complications: both involved 
CRPS reactions, leading to longer rehabilitation and hand therapy. Both patients fully 
recovered at one-year. There were no wound healing complications and none of the 44 
hands treated with PALF suffered a neurovascular or tendon injury. Three patients (9%) in 
the LF-group developed severe complications: one patient developed a persistent CRPS, 
which led to a serious loss of function of this hand at one year after surgery. Two of the 32 
LF treated hands suffered a neurovascular injury (6%), one had an intraoperative arterial 
lesion, which was immediately reconstructed. The other suffered an intraoperative nerve 
To
ta
l P
as
si
ve
 e
xt
en
si
on
 d
efi
ci
t (
TP
ED
) (
de
gr
ee
s)
int
erv
en
tio
n
2 w
ee
ks
3 w
ee
ks
pr
e -
 in
ter
ve
nti
on
6 m
on
ths
1 y
ea
r
Follow - up 1 year
PALF
LF
0
10
20
30
40
50
60
70
1 year post PALF1 year post LF
figure 4: Contracture correction in total passive extension deficit (TPED): goniometric outcomes mea-
sured preoperatively and at two weeks, three weeks, six months and one-year after surgery. This graphs 
shows the total passive extension deficit (TPED) between PALF and LF. Photographs below the graph 
show the difference in amount of contracture for each technique measured at one year.
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lesion, which was immediately reconstructed but led to loss of sensation one year after 
surgery. After one year, two patients of the LF-group still had persistent problems result-
ing from their surgery versus none of the patients of the PALF-group.
DIScuSSIon
The aim of this prospective single-blinded randomized study was to compare percuta-
neous aponeurotomy and lipofilling (PALF), a novel minimally invasive procedure, with 
the gold standard LF in the treatment of patients with primary Dupuytren’s contracture. 
We found no significant difference in contracture correction as both groups obtained 
almost full MP-joint contracture release that persisted for the entire one year follow up, 
while some residual extension contracture remained and persisted for the PIP-joint in 
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both groups. However, PALF-treated hands healed significantly faster, returned earlier 
to their normal daily activity, and were able to make a full fist significantly earlier than 
LF-treated hands. At one-year postoperatively, there were no significant differences 
between groups in terms of recurrence rate and hand function. Patient satisfaction was 
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similar in both groups at six months and was better at one year in the LF-group. The 
LF-group had a six percent permanent complication rate compared to zero percent in 
the PALF-group; this was however not significant with the present sample size.
The PALF technique used in the present study differs from conventional needle apo-
neurotomy (NA) in many aspects. First, PALF is performed in the OR under regional 
block anesthesia and tourniquet ischemia while NA is commonly performed in the of-
fice under limited dermal anesthesia. Second, in PALF, the fibrous cord is disintegrated 
using an extensive percutaneous needle aponeurotomy technique, applying numerous 
(up to 40) superficial nicks along the entire extent of the cord while it is maintained 
under a strong extension force, whereas NA releases the cord by transecting it only at a 
couple of locations without specifically applying an extension force. Herein lies a ma-
jor technical difference; by continuously providing maximal tension as the contracture 
is released, the small nicks are more likely to cut the tight cords that restrict extension 
than the looser neurovascular bundles. Tension also allows the surgeon to localize the 
residual restricting bands by palpation. Therefore, while the safety of NA is provided by 
dermal anesthesia that preserves protective sensation to the underlying nerve, it is the 
differential cutting ability of a needle for structures under strong tension that provides 
the PALF safety.
The other major distinction with NA is lipofilling. The multiple nicks of PALF trans-
form the solid cord into a recipient scaffold that provides space and interface for fat 
graft survival. Fat grafting restores the subdermal fat deficiency of DD and acts as inter-
before PALF
operation
2 weeks 
after PALF
patient 1
patient 2
figure 7: This figures shows to different examples of patients treated with PALF. Patient A is suffering of 
DD of the fifth digit. Patient B is suffering of DD of the first, fourth and fifth digit.
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posed tissue to prevent the transected fibers from re-scarring together(9). Furthermore 
lipoaspirate is known to contain stem cells that can treat fibrotic diseases and inhibit 
proliferation of contractile myofibroblasts responsible for DD through soluble factors(8).
The study by van Rijssen comparing conventional NA with LF found that the degree of 
initial contracture correction was similar among groups but that recurrence rates were 
much higher in the NA-group(3, 6). The present study also shows that PALF yields similar 
outcome correction as LF, but with no difference in recurrence at one year after surgery. 
However, PIP-joint corrections show a trend that might indicate more recurrences for 
PALF over a longer follow-up. A long-time outcome (e.g. five years) may be valuable 
to further evaluate this trend. Furthermore, similar to us, van Rijssen found 5% severe 
complications after LF-group and 0% after NA, compared to 9% after LF and 5% after 
PALF in our study(3). Clearly, LF is more complication prone than both NA and PALF.
Concerning satisfaction, no significant difference was measured between LF and 
PALF at six months. Since no general satisfaction questionnaires are available to our 
knowledge, we asked a number of specific questions concerning satisfaction. However, 
these questions were not validated before. Furthermore, since the main difference in 
hand function was found at three weeks post intervention it is possible that satisfaction 
was different at that specific time point as well. Most patients will forget their fast recov-
ery at six months and one year, however they may have different problems concerning 
less straight fingers or recurrence.
We have extensive clinical experience, beside this clinical trial, with this procedure. 
Our experience confirms the safety of PALF; we have only transected one nerve and 
one tendon in more than 400 Dupuytren digital contractures released with PALF over 
the past eight years(7, 12). Furthermore, PALF avoids the morbidity of flaps and grafts; 
only two very severe cases required a small transposition flap in the past eight years. 
This is because the staggered nicks of PALF expand the contracture to address the tissue 
deficiency in a fashion akin to mesh-expansion of a skin graft. Fat grafting the tiny 
slit interstices then regenerates the missing tissue. Khouri et al. have shown that PALF 
can also be used to treat other contractures and is a minimally invasive regenerative 
alternative to the classic flap transfers(16).
The strength of this study is that it is one of the few randomized controlled trials for 
DD. However, it also has some limitations. Powered to detect a difference in contrac-
ture correction, it may not be sufficiently powered to detect potential differences for 
other outcome variables, such as DASH score, pain score and recurrence rate. In our 
recent unpublished studies the Michigan Hand Questionnaire has taken over the DASH 
questionnaire, as the DASH does not distinguish hand conditions very well. Further-
more, more patients dropped out from LF and we cannot exclude this was because they 
were unhappy with this allocation. However, despite of this, both groups were similar 
at baseline.
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In our statistical analysis, we only analyzed the pre-operatively most affected digit in 
order to avoid outcome measures dependency with multiple fingers and joints analyzed 
within the same patient(17). Since only the most severe contractures were included, our 
data may underestimate contracture correction in both groups. While this should be 
taken into account when comparing our results with others, it should not influence the 
direct comparison between groups in our study.
Because the trial has only two arms with LF as the control standard reference, we 
cannot determine whether the outcome is due to a more elaborate and extensive apo-
neurotomy than NA, to the addition of lipofilling, or most likely, to their combination(18). 
However, early in our experience, when we performed the extensive aponeurotomy 
without lipofilling our patients had rapid recurrences just as in NA. It is only after 
we brought in the biologic, anti-fibrotic effect of fat grafting that the recurrence rate 
dropped.
Because it is minimally invasive, PALF has the great advantage of being able to simul-
taneously address multiple digital rays, and can be performed repetitively something LF 
cannot safely offer. PALF is a radical departure from the invasive excisional surgery, in-
stead of removing the pathology; it treats the fibrosis by morselizing it and adding tissue 
with regenerative potential. In a sense, PALF is a regenerative alternative to traditional 
excisional surgery and flaps in the treatment of DD. While it is not a panacea and it 
might not affect the course of severe Dupuytren diathesis, this prospective randomized 
study shows that PALF offers a similar degree of contracture correction for the first year 
as the gold standard LF with a faster recovery and lesser long-term complications. We 
conclude PALF is a safe and effective treatment for DD. While it should be offered in 
the whole spectrum of treatment modalities of DD, it is currently our preferred treat-
ment alternative for primary Dupuytren contractures.
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General discussion
This thesis presents research on the effectiveness of an innovative treatment for 
Dupuytren’s disease (DD) as well as a number of methodological studies related to 
evaluating effectiveness of DD treatment and patient preferences for specific treatment 
characteristics. In the following sections we elaborate on the main findings in this thesis 
and discuss the implications these might have on research and treatment on DD. In 
addition, possible directions for future research will be discussed.
tHE EffEct of DIffEREnt DEfInItIonS foR REcuRREncE AnD A nEw 
DEfInItIon
Reporting recurrence rates is an essential part of evaluating the effectiveness of treat-
ment for DD(1). In chapter 2, we reviewed the different definitions for recurrence after 
treatment of DD in literature and we evaluated the effect of these different definitions 
on the resulting recurrence rate. We found that 51% of the publications reporting recur-
rence rates did not present a definition of recurrence(2). The reported definitions could 
be grouped into three main categories, based on 1) the return of nodules and cords, 2) 
the return of joint contractures, or 3) the patient’s self-report of a recurrence or whether 
a recurrent surgery was performed(2). Furthermore, we found that recurrence rates at 
six months follow-up can range from 2 to 86% in the same dataset of DD patients, 
based on applying different thresholds for degrees of contracture, different baseline 
measurements, and different selected joints (Figure 1)(3-11).
Due to the lack of a uniform definition and the results from chapter 2 showing the 
very large effects of applying different definitions on the same dataset, we decided 
to develop a new definition for recurrence of DD using a Delphi method with an 
international group of experts (chapter 3)(12). After five consensus rounds, the experts 
agreed to define recurrence as “an increase in joint contracture in any treated joint of at 
least 20 degrees at one-year post-treatment compared to six weeks post-treatment.” This 
new definition will give us the opportunity to compare the effectiveness of treatments 
for DD in near future when applied by different authors in the same way.
While we believe that this new definition is an important step forward, lack of clearly 
defined outcome measures may still apply to several other aspects of DD treatment. For 
example, an internationally recognized guideline for measuring joint angle is presently 
lacking. Since there is no agreement on how joint angles should be measured this 
may lead to differences between studies. For instance, should a joint be measured 
passively or actively? Furthermore, should the outcome of different joint measurements 
be combined, which is done when presenting a total passive extension deficit (TPED) 
or a total flexion movement (TFM), or presented separately? In addition, hand func-
tion is often studied by using a questionnaire(11). The questionnaire most often used to 
measure hand function of patients with DD is the Disability of the Arm Shoulder and 
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Hand (DASH) questionnaire. As the name implies, this questionnaire is not primarily 
designed for patients with only hand problems, such as patients suffering of DD(13, 14). 
As a result, patients suffering of DD express that the disabilities they experience are not 
even mentioned in the questionnaire, such as grabbing things under a closet, trying on 
gloves, etcetera. This will result in DASH scores that might imply less disability than 
patients’ actual experience.
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figure 1: Relation between the acquired extension deficit and the recurrence rate in the single dataset. 
The extension deficit was based on the most affected joint per hand (n = 66). The lower dark line rep-
resents the difference in joint angle between two weeks postoperative and six months postoperatively. 
For example, when one degree extension deficit is applied as a threshold for recurrence, we found that 
55% of our patients had a change in angle that exceeded this threshold and that would therefore have 
a recurrence. With a 30 degrees threshold, however, only six percent of our cohort has a recurrence. 
The upper light-grey line indicates the same threshold in angle, however using peroperative data as the 
initial baseline data instead of data two weeks postoperative.
Furthermore the TPED was used instead of the most affected joint. The vertical lines are the specific 
angular thresholds used in different articles; they indicate how these different thresholds lead to incom-
parable recurrence rates when applied to the same data. *Used TPED for the definition
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Another outcome measure that may need international consensus is the aspect of ‘pa-
tient satisfaction’. First of all, satisfaction questionnaires asking about the outcomes of 
Dupuytren interventions are presently lacking to our knowledge. As a result, research-
ers make their own questionnaires that often include ‘yes’ or ‘no’ questions or a visual 
analog scale (VAS)(15, 16). Beside the fact it is also never been invested if ‘satisfaction’ is 
best measured with ‘yes’ or ‘no’ or ‘VAS’ questions, these questionnaires are also never 
validated. For example the question ‘are you satisfied with the outcome of the surgical 
treatment?’ can be interpreted in many ways, such as: are you satisfied that your finger 
is straight again, or are you satisfied your hand function has been improved, or maybe 
are you satisfied with how the scar looks’?
The last outcome measures we want to address and that may need more international 
consensus are complications and complication rates. When describing new treatment 
interventions it is imminent to describe the complications of that intervention. In many 
studies these complications are subcategorized in minor and major complications(6, 
11). However, in some studies, definitions of these minor or major complications are 
lacking. Besides the fact that it is hard to define a complication, it may be even harder 
to evaluate all complications during a study follow up. For example, not all patients 
seek for help by their surgeon with a hematoma or numbness of the finger or edema of 
the hand. They might go to the general practitioner (GP) instead. On the other hand, is 
edema of the hand a complication when you have operated the entire hand for DD? 
We have described that it is difficult to define, assess and categorize complications. 
Therefore, it may seem obvious when only the overall complication rates are presented 
in a study it may not give the reader transparent information.
It should be noted that we do not believe that it is possible to reflect the complexity of 
recurrence and other outcome measures for DD in a single definition or single outcome 
measure. However, it is necessary to find consensus in how to measure and present 
outcome measures when describing DD interventions, so it will be possible to compare 
studies and effectiveness of DD interventions in the best manor in near future.
Patient-rated importance of different characteristics of DD treatment
In chapter 4 we present a study on which characteristics of DD treatment are rated by 
patients as most important, such as contracture correction, recurrence and complica-
tions. Insight in patients’ preferences can contribute to patient-centered care and in-
formation for patients. In addition, understanding which aspects of treatment are most 
valuable for patients can help us to determine which outcome parameters of treatment 
should be evaluated when comparing treatments. Therefore, we performed a discrete 
choice experiment (DCE) including a large study population (506 analyzed question-
naires). We found that recurrence rate (36%) and extensive deficit (28%) were the most 
important attributes in making treatment choices, followed by minor complication rate 
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(13%) (Table 1). Multiple trade-offs could be calculated, for example patients accepted 
an increase of 11% recurrent disease if they could receive NA treatment instead of LF.
A number of the findings of the DCE were, in our experience, surprising. For ex-
ample, we found that minor complications were more important for patients compared 
to major complications. An explanation may be that patients are more focused on the 
minor complications since it is more obvious to encounter minor complications (such 
as edema, hematoma) after an intervention than major complications (such as nerve 
lesions and infections).
A second surprising finding may be that patients in our study prefer low recurrence 
rates and less extension deficit above the short convalescence. This may be surprising 
since minimally invasive treatment interventions are increasingly popular and consid-
ered beneficial for many patients(6, 16-18). The focus towards the minimal invasive tech-
niques may be related to a number of factors, such as decreased direct medical costs, 
decreased indirect costs due to less absence of work, and complaints from patients 
about long convalescence after intervention(19-21). However, patients’ preferences for 
different characteristics of DD treatment have never been directly studied. Our findings 
may indicate that patients focus mainly on solving the problem, which is a contracture 
correction, with a minimal chance of having a recurrent contracture. Convalescence 
is than considered less important. Our findings may indicate that patients suffering of 
DD may make different choices than their treating hand surgeons. In future, it may be 
interesting to compare hand surgeons’ preferences and patients’ preferences.
long-term results of flap surgery for severe diathesis
In chapter 5 we were interested in the treatment of the relatively small group of patients 
with very severe diathesis(22). These specific patients are known to have a poor surgical 
Important scores (IS)
Latent class 1 Latent class 2 Latent class 3 Overall
Recurrence rate within 5 years 27.2% 28.7% 43.9% 36%
Residual extension deficit after treatment 49.3% 21.6% 12.8% 28%
Minor complication rate 5.9% 9.4% 18. 9% 12%
Treatment method 4.4% 27.7% 8.4% 9%
Major complication rate 3.8% 5.6% 7.2% 6%
Convalescence 3.1% 3.4% 6.1% 5%
Aesthetic result 6% 3.6% 2.6% 4%
table 1: The importance scores are calculated rates, indicating how much one decision is based on a 
specific attribute (e.g., x% of the decision for a specific treatment option is based on recurrence rate, 
and y% of the decision is based on reduction of extension deficit; all rates together count up to 100% 
and counts as 1 decision for a specific treatment). The relative importance of the different attributes was 
different between the subjects belonging to the different latent classes.
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outcome with a recurrence or extension rate up to 47% even after dermofasciectomy(23, 
24). In Rotterdam, we have performed a radical fasciectomy and extensive flap surgery 
for both hands and feet in these specific patients. In this chapter, we describe the long-
term outcome (25 years after treatment) of a case-series of two brothers with a severe 
diathesis of DD. We found that hand function was acceptable and both patients were 
very satisfied with the overall results following the flap surgery. Most importantly, no 
recurrence developed under the flaps. In this study, we demonstrated that patients with 
severe diathesis sometimes need special and radical surgical interventions by using 
either pedicled axial flaps or free vascularized flaps. In the past, studies using free 
vascular flaps for soft tissue coverage after palm and digit defects for DD patients have 
been reported(25-27). However, these studies only focused on survival of the flap and 
not on recurrence of DD and hand function. Although we only describe two patients, 
our results suggest that large flap surgery should be considered as an aggressive but 
alternative treatment for patients with severe DD.
Results of the PAlf surgery
The last part of this thesis compared the outcome of an innovative extensive percuta-
neous aponeurotomy and lipofilling (PALF) technique with the most commonly used 
surgical technique, limited fasciectomy (LF). First, in chapter 6 we evaluated first ret-
rospectively the outcome of patients treated with PALF in Miami and Rotterdam (Figure 
2). Despite this study was originally designed to describe the surgical method we were 
able to report goniometry data of 50 of the 91 patients. We found that MP-joint and 
PIP-joint contractures could be successfully treated with this new technique, including 
the more severe contractures. Patients reported a short recovery time and were satisfied 
with the results(15). However, a randomized controlled trial was needed to compare this 
new treatment with a golden standard.
Therefore, in chapter 7, we presented data of a single blind multicenter randomized 
controlled trial (RCT). We found that in both PALF and LF, almost full MP-joint contrac-
ture was obtained while for the PIP-joint some residual contracture remained. How-
ever, we found no significant differences in contracture correction between groups. In 
addition, we found that patients in the PALF-group returned significantly earlier to their 
normal daily activity while at one-year post surgery, we found no significant differences 
in recurrence rate and hand function (Figure 3 and Figure 4). At one year after surgery, 
LF-treated patients were significantly more satisfied on the overall treatment outcome, 
contracture correction, and whether treatment expectations were met. However, no 
significance difference was found in percentages of patients who wanted to receive the 
same operation again and who wanted to recommend their type surgery to family and 
friends. Also all other satisfaction-related questions were similar between groups.
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figure 2: PALF technique illustration: preoperative photo of a patient with a Dupuytren contracture of 
the fifth digit on the right hand (A). Making of multiple nicks from proximal to distal with a 19-gauge 
needle (B and D). Releasing dermal attachments of the cord with a windshield wiper motion of an “L” 
shaped needle (C, E and F). Placement of the digital contractures under maximal tension in extension, 
using a firm hand retractor during the whole operation (G). The hand is ready for lipografting once the 
contracture is fully released (H). Injection of 8-10 ml. of non-centrifuged, simply sedimented lipoaspi-
rate per digital ray (I). Plaster extension splinting, kept on for five to seven days (J).
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The results from the cohort study (chapter 6) and the RCT (chapter 7) together show 
that extensive percutaneous needle aponeurotomy with lipofilling (PALF) is a good 
technique to treat patients with DD. Especially patients suffering of MP-joints contrac-
tures are good candidates for this technique. Furthermore, patients suffering of DD 
in multiple rays can be treated in one surgical session in contrast with LF were more 
surgeries might be needed.
An important challenge in analyzing the results of the trial is the fact that individual 
patients can be operated on one of both hands, one or more fingers, and, within a 
finger, one or more joints(28). To solve this problem, for analysis of all the RCT data 
(chapter 7), we selected the most severely affected finger. In this way we were able to 
simplify the problem that some patients are suffering of DD in more than one finger on 
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figure 3: Total flexion movement (TFM): goniometric outcomes measured preoperatively and at two 
weeks, three weeks, six months and one-year after surgery. This graph shows the difference of the abil-
ity to make fist as a measure of convalescence based on the total flexion movement of all joints (TFM). 
Photographs below the graph show the difference in the ability of making a fist measured at two weeks 
post surgery.
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the same hand. This was earlier suggested in a review, which described the statistical is-
sues when dealing with both hands and/or multiple affected fingers(28). Since we found 
no significant difference in the amount of affected fingers between the PALF-group and 
LF-group, we feel there is no bias between these groups. However we may overestimate 
the residual deficit and the amount of relapse of both groups since it is known that 
more affected fingers are less likely to treat to full release and are more prone to relapse 
sooner.
We decided, when designing the randomized trial, to use LF as a control group be-
cause we considered LF the most commonly used treatment for this patient group. As a 
result, we cannot establish whether differences in outcome are related to this particular 
extensive needle aponeurotomy technique compared to standard needle aponeurotomy 
or related to the lipofilling, or both. We know that in-vitro studies showed fat stem 
cells to be beneficial in inhibition of the contractility of the myofibroblast(29). However, 
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figure 4: Contracture correction in total passive extension deficit (TPED): goniometric outcomes mea-
sured preoperatively and at two weeks, three weeks, six months and one-year after surgery. This graphs 
shows the total passive extension deficit (TPED) between PALF and LF. Photographs below the graph 
show the difference in amount of contracture for each technique measured at one year.
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in-vivo studies such as a comparison with PALF and needle aponeurotomy would be 
needed to determine if the extensiveness of the needle aponeurotomy and the addition 
of fat are in conjunction better than needle aponeurotomy alone. This will be studied 
in the near future by matching our RCT data with prospective collected conventional 
aponeurotomy data of the Xpert Clinic.
For both the prospective cohort as well as the RCT, no long-term follow-up data 
beyond one year is yet available. Therefore long-term recurrence rates cannot be 
presented. In future, we will measure the patients treated with PALF and LF again at 
five-year follow-up. Since we found that patients prefer contracture correction and 
low recurrence rates above short convalescence, these future data on recurrence are 
of great value to guide patients straightforward in making the decision of being treated 
with PALF or LF.
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English summary
This thesis presents research on the effectiveness of an innovative treatment for Dupuy-
tren’s disease (DD) as well as a number of methodological studies related to evaluating 
effectiveness of DD treatment and patient preferences for specific treatment character-
istics. In the following sections we briefly summarize the outcome of all studies.
tHE EffEct of DIffEREnt DEfInItIonS foR REcuRREncE AnD A nEw 
DEfInItIon
Recurrence rates are important in evaluating effectiveness of treatment for Dupuytren’s 
disease (DD). In literature, recurrence rates vary between 0% and 100% and the definition 
of recurrence of DD after treatment is inconsistently used. In chapter 2, we reviewed the 
different definitions for recurrence after treatment of DD in literature and evaluated the 
effect of these different definitions on the resulting recurrence rate. We found that 51% of 
the publications reporting recurrence rates did not present a definition of recurrence. The 
reported definitions could be grouped into three main categories, based on 1) the return 
of nodules and cords, 2) the return of joint contractures, or 3) the patient’s self-report of a 
recurrence or whether a recurrent surgery was performed. Furthermore, recurrence rates 
at six months follow-up ranged from 2 to 86% in the same dataset of DD patients, based 
on applying different angular thresholds, different baseline measurement, and different 
selected joints. Based on this, we conclude that it is presently difficult or even impossible 
to compare recurrence rates between different treatments reported in the literature and 
that consensus on a recurrence definition is needed.
Based on the results from chapter 2, we decided to develop an expert consensus 
definition for recurrence of DD (chapter 3). To do so, we used the Delphi method and 
invited 43 Dupuytren’s research and treatment experts from 10 countries to participate 
by answering a series of questionnaire rounds. After each round the answers were 
analyzed and the experts received a feedback report with another questionnaire round. 
Twenty-one experts agreed to participate in this study. After four consensus rounds, 
they agreed that DD recurrence should be defined as “more than 20 degrees of con-
tracture recurrence in any treated joint at one year post-treatment compared to six 
weeks post-treatment”. In addition, it was recommended that recurrence should be 
reported individually for every treated joint and that ideally measurements should be 
repeated and reported yearly.
PAtIEnt-RAtED ImPoRtAncE of DIffEREnt cHARActERIStIcS of DD 
tREAtmEnt
While in modern medicine, patients’ preferences are important; these have never been 
defined for characteristics of Dupuytren treatment. Insight in these patients’ preferences 
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can contribute to patient-centered care and information for patients. Furthermore, 
understanding which aspects of treatment are most valuable for patients can help us to 
determine which outcome parameters of treatment should be evaluated when compar-
ing treatments. In chapter 4 we present a multicentre discrete choice experiment on 
which characteristics of DD treatment are rated by patients as most important. Patients 
were asked on their preferences for attributes of Dupuytren treatments using scenarios 
based on treatment method, major and minor complication rates, recurrence rates, 
convalescence, residual extension deficit after treatment and aesthetic results. The 
relative importance of these attributes and the trade-offs patients were willing to make 
between them were analysed using a panel latent class logit model.
Five-hundred-and-six patients filled in the questionnaire. All above-mentioned at-
tributes proved to significantly influence patients’ preferences for Dupuytren treatment 
and preference heterogeneity was substantial; males who perform heavy labour made 
different trade-offs than females or males who did not. In general, recurrence rate (36%) 
and extensive deficit (28%) were the most important attributes in making treatment 
choices, followed by minor complication rate (13%). Patients accepted an increase 
of 11% recurrent disease if they could receive needle aponeurotomy (NA) treatment 
instead of limited fasciectomy. We concluded that this study confirms the importance 
of low recurrence rates and complete contracture corrections, but also emphasizes the 
significance of low complication rates. The preference heterogeneity shows that patient 
consultations need to be targeted differently, which may result in different treatment 
decisions depending on patient characteristics and preferences.
lonG-tERm RESultS of flAP SuRGERy foR SEVERE DIAtHESIS
In chapter 5 we were interested in the treatment of this relatively small group of patients 
with very severe diathesis, which are known to have a poor surgical outcome with a 
recurrence rate up to 47% after dermofasciectomy. In Rotterdam, we have performed ex-
tensive flap surgery for both hands and feet and in this chapter, we describe the long-term 
outcome (14 to 25 years after treatment) of a case-series of two brothers with a severe 
diathesis of DD. We found that hand function was acceptable and that both patients were 
very satisfied with the overall results following the flap surgery. Importantly, no recur-
rence developed under the flaps. We concluded that in very severe diathesis, flaps should 
be considered in an earlier phase to prevent multiple procedures and early recurrence.
RESultS of tHE PAlf SuRGERy
Surgical resection of Dupuytren’s contracture is fraught with morbidity and prolonged 
recovery. In chapter 6 we introduce an innovative extensive percutaneous aponeu-
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rotomy and lipofilling (PALF) technique and describe the early results. This procedure 
consists of an extensive percutaneous aponeurotomy that completely disintegrates the 
cord and separates it from the dermis. Subsequently the resultant loosened structure 
is grafted with autologous lipoaspirate. After one week of post-operative extension 
splinting, patients are allowed normal hand use and are advised to use night splints for 
3-6 months. In this chapter, we report on our experience with 91 patients (99 hands) 
operated in Miami and Rotterdam; from 50 patients we report on goniometry (average 
follow-up of 44 weeks). We found that the contracture from the PIP-joint improved 
significantly from 61 degrees to 27 degrees and the MP-joint from 37 degrees to −5 
degrees. Ninety-four percent of patients returned to normal use of the hand within 2–4 
weeks and 95% were very satisfied with the result. No new scars were added and a 
supple palmar fat pad was mostly restored. Complications were one digital nerve injury, 
one post-operative wound infection and four patients with CRPS. We concluded that 
this new invasive technique shortens recovery time, adds to the deficient subcutaneous 
fat and leads to scarless supple skin. By its ability to treat multiple rays, it addresses the 
pathology in the entire hand.
However, since chapter 6 did not include a comparison group, a randomized con-
trolled trial was needed to directly compare this new treatment with a golden standard. 
Therefore, in chapter 7, we designed a single-blind multicenter randomized trial com-
paring the effectiveness of PALF with limited fasciectomy (LF). Patients with a primary 
Dupuytren’s contracture of at least 20° (MP-joint) or 30° (PIP-joint) were randomly 
assigned to the LF-group or the PALF-group. Patients were measured at baseline and at 
two weeks, three weeks, six months and one year post-operatively. Primary outcome of 
the trial was contracture correction and convalescence.
Eighty patients with 88 treated hands were included in this study and randomized 
to PALF or LF treatment. In both groups, almost full MP-joint contracture was obtained 
while for the PIP-joint some residual contracture remained. However, no significant 
differences in contracture correction between groups were detected. In addition, the 
patients in the PALF-group returned significantly earlier to their normal daily activity. 
At one-year post surgery, no significant differences in recurrence rate and hand func-
tion were present. We concluded that PALF is a valuable addition to the treatment 
methods of DD, showing similar operative contracture correction to LF treatment and 
no significant difference regarding one-year postoperative results and a significantly 
shorter convalescence.
In chapter 8 we discuss our main findings of all studies, furthermore we make some 
suggestions for future research purposes.
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In dit proefschrift wordt onderzoek naar de effectiviteit van een nieuwe behandeling 
van Morbus Dupuytren (M. Dupuytren) beschreven. Ook komen er verschillende 
methodologische studies aan bod naar de effectiviteit van de behandelingen van M. 
Dupuytren en een studie naar patiënten voorkeuren. In de volgende alinea’s zullen we 
de uitkomsten van deze verschillende onderzoeken kort beschrijven.
HEt EffEct VAn VERScHIllEnDE DEfInItIES VooR DE tERuGKEER VAn DE 
zIEKtE VAn DuPuytREn
Het percentage patiënten met een terugkeer van M. Dupuytren na operatie is een be-
langrijke parameter om de effectiviteit van de verschillende behandeling te evalueren. 
In de literatuur worden percentages beschreven variërend tussen de 0% en 100%, 
waarbij  de terugkeer van M. Dupuytren zeer inconsequent gedefinieerd wordt. In 
Hoofdstuk 2 hebben we de verschillende definities beschreven en hebben we ge-
evalueerd wat het effect van deze verschillende definities was op de gerapporteerde 
terugkeer van M. Dupuytren binnen een cohort van patiënten. We vonden dat 51% van 
de publicaties geen definitie beschrijft. Verder konden we de gepubliceerde definities 
onderverdelen in drie categorieën. Deze categorieën waren gebaseerd op 1) de terug-
keer van nodules en strengen, 2) de terugkeer van gewrichtscontracturen, en 3) de door 
patiënten zelf-gerapporteerde terugkeer van ziekte of het ondergaan van een nieuwe 
operatie. Bovendien konden we aantonen dat de percentage terugkeer van ziekte kun-
nen variëren tussen 2% en 86% in dezelfde dataset van patiënten, afhankelijk van de 
gekozen definitie. Daarom concluderen we dat het tot op heden niet mogelijk is om 
verschillende percentages van verschillende studies met elkaar te vergelijken. Daarom 
is een consensus over een nieuwe definities noodzakelijk. 
De resultaten van Hoofdstuk 2 hebben geleid tot Hoofdstuk 3, waarin we samen 
met experts een definitie voor de terugkeer van M. Dupuytren hebben ontwikkeld. 
In totaal zijn er 43 experts uit 10 verschillende landen op gebied van M. Dupuytren 
gevraagd mee te doen aan een Delphi studie. In verschillende ronden werd gevraagd 
om verschillende vragen te beantwoorden. Na elke ronde werden de antwoorden 
geanalyseerd en een feedbackrapport terug gestuurd naar de experts. Op basis daarvan 
werden eventueel nieuwe vragen gesteld. Uiteindelijk deden er 21 experts mee aan 
deze studie. Na vier ronden werd er consensus bereikt waarbij de terugkeer van M. 
Dupuytren werd gedefinieerd als: ‘een terugkeer van ten minste 20 graden flexie con-
tractuur in een geopereerd gewricht gemeten op een jaar na behandeling vergeleken 
met zes weken na de behandeling’. Tevens werd er door de experts geadviseerd om de 
gewrichten afzonderlijk van elkaar te vermelden en om metingen waar mogelijk elk 
jaar te herhalen. 
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PAtIëntVooRKEuREn VooR VERScHIllEnDE KARAKtERIStIEKEn VAn DE 
bEHAnDElInG VAn m. DuPuytREn. 
Patiëntvoorkeuren worden in de gezondheidszorg steeds belangrijker, maar zijn nog 
nooit bestudeerd voor de behandeling naar M. Dupuytren. Inzichten in deze patiënt-
voorkeuren kunnen een bijdrage leveren aan doelgerichte zorg waar de patiënt centraal 
staat. Daarbij kan het begrijpen van patiëntvoorkeuren helpen de juiste uitkomstpara-
meters te kiezen in een onderzoek.
In Hoofdstuk 4 presenteren we een multicenter discrete choice experiment (DCE) 
naar karakteristieken van de behandeling van M. Dupuytren die door patiënten als 
‘meest belangrijk’ worden gescoord. Patiënten werd naar hun voorkeur gevraagd via 
een vragenlijst waarin hypothetische behandelscenario’s werden voorgelegd. Deze 
scenario’s verschilden op basis van behandelmethode, incidentie van complicaties, 
terugkeer van ziekte, snelheid van herstel, rechtheid van de vinger na de behandeling 
en esthetisch resultaat. De relatieve belangrijkheid van deze attributen en de trade-offs 
die patiënten bereid zijn te maken tussen deze attributen werden geanalyseerd. 
Vijfhonderden-zes patiënten hebben de vragenlijst ingevuld. Alle hierboven be-
schreven attributen beïnvloedden significant de patiëntvoorkeuren bij een Dupuytren 
behandeling. Over het algemeen waren terugkeer van ziekte (36%) en rechtheid van de 
vinger na behandeling (28%) voor patiënten de meest belangrijke attributen, gevolgd 
door milde complicaties (13%). Patiënten accepteerden verder een 11% hoger risico 
op terugkeer van ziekte als zij behandeld konden worden met naaldaponeurotomie in 
plaats van selectieve fasciectomie. We concluderen uit deze studie dat lage kans op 
terugkeer van ziekte en volledige rechtheid van vingers na een behandeling de belang-
rijkste attributen zijn voor patiënten, gevolgd door een kleine kans op complicaties. 
lAnGE tERmIJn RESultAtEn VAn lAP oPERAtIE VooR PAtIëntEn mEt 
EEn ERGE DuPuytREn DIAtHESE 
In Hoofdstuk 5 waren we geïnteresseerd in een behandeling van een relatief kleine 
groep patiënten met een ernstige Dupuytren diathese. Het is algemeen bekend dat deze 
patiëntengroep een grote kans heeft op terugkeer van de ziekte. Er zijn percentages 
terugkeer van M. Dupuytren beschreven van meer dan 47% na een dermofasciectomie. 
In Rotterdam hebben we uitgebreide (vrije danwel gesteelde) lap operaties verricht 
aan de handen en voeten van verschillende patiënten. In dit hoofdstuk beschrijven we 
de lange termijn resultaten (14 tot 25 jaar na behandeling) van twee broers met een 
ernstige Dupuytren diathese. We vonden dat handfunctie redelijk was en dat beide 
patiënten erg tevreden waren met het gehele resultaat na de lap operatie. Belangrijk 
is dat er geen terugkeer van M. Dupuytren was onder de lappen. We kunnen hieruit 
concluderen dat bij een ernstige Dupuytren diathese (vrije en gesteelde) lappen eerder 
145
Nederlandse Samenvatting
moeten worden overwogen om te voorkomen dat deze patiënten veelvuldig worden 
geopereerd. 
RESultAtEn VAn PAlf cHIRuRGIE 
Chirurgische resectie van een Dupuytren contractuur heeft een relatief hoge morbi-
diteit en lange herstelperiode. In Hoofdstuk 6 hebben we een nieuwe innovatieve 
chirurgische methode geïntroduceerd, de uitgebreide percutane aponeurotomie en 
lipofilling (PALF). Deze methode bestaat uit een uitgebreide percutane naaldaponeuro-
tomie waardoor de Dupuytren streng volledig uit elkaar valt en los maakt van de huid. 
Vervolgens wordt er tussen de huid en de kapotte streng autoloog vet geïnjecteerd. 
Gedurende een week na de operatie heeft de patiënt een extensie spalk, daarna wordt 
er geadviseerd om wederom te starten met normale handfunctie en een nachtspalk 
voor drie tot zes maanden. In dit hoofdstuk beschrijven we onze ervaringen van 91 
patiënten (99 handen) die zijn geopereerd in Miami en Rotterdam. Van 50 patiënten 
konden we ook goniometrische data presenteren met een gemiddelde follow-up van 
44 weken. We vonden dat het PIP-gewricht significant was verbeterd van 61 graden 
naar 27 graden en dat het MCP-gewricht van 37 graden naar -5 graden verbeterde. 
Vierennegentig procent van de patiënten hadden binnen twee tot vier weken weer 
een volledige handfunctie en 95% was tevreden met het resultaat. Er werden geen 
nieuwe littekens gemaakt en het palmaire vet werd in de meeste gevallen hersteld. 
Wel werden er verschillende complicaties gezien, waaronder een digitaal zenuwletsel, 
een postoperatieve wondinfectie en vier patiënten ontwikkelde een CRPS. We kunnen 
concluderen dat deze nieuwe minimaal-invasieve methode een kortere herstelperiode 
heeft vergeleken met de conventionele technieken. Verder hebben we gezien dat het 
toevoegen van vet leidt tot een soepele huid in de palm van de hand met weinig lit-
tekens. Omdat het bij deze techniek mogelijk is om meerdere aangedane stralen te 
behandelen kan bovendien pathologie van een gehele hand worden behandeld.
Omdat er in Hoofdstuk 6 naast de patiëntengroep die behandeld werden met PALF 
geen controlegroep aanwezig was, was een gerandomiseerde studie nodig om de 
nieuwe techniek te vergelijken met een gouden standaard. Daarom hebben we een 
enkel-geblindeerde multicenter gerandomiseerde studie opgezet waarbij we het effect 
van PALF vergelijken met de selectieve fasciectomie (SF), beschreven in Hoofdstuk 7. 
Patiënten met een primaire Dupuytren contractuur van ten minste 20° (MCP-gewricht) 
of een 30° (PIP-gewricht) werden gerandomiseerd over de SF-groep en PALF-groep. 
Patiënten werden preoperatief, op twee weken, drie weken, zes maanden en een jaar 
post-operatief gemeten. De primaire uitkomstmaten waren contractuurcorrectie en 
herstelperiode. 
Chapter 10
146
Tachtig patiënten met 88 geopereerde handen werden geïncludeerd in deze studie 
en gerandomiseerd tussen PALF en SF. In beiden groepen werd een bijna volledige 
MCP-contractuurcorrectie behaald, hoewel er voor het PIP-gewricht een postopera-
tieve extensiebeperking bleef bestaan. Er was geen significant verschil in contractuur-
correctie tussen de twee groepen. Wel konden patiënten in de PALF-groep significant 
eerder hun dagelijkse activiteiten uitvoeren. Een jaar na de behandeling werd er geen 
verschil gevonden in ratio van terugkeer van ziekte en handfunctie. We concluderen 
dan ook dat PALF een waardevolle toevoeging is in het palet van behandelingen van 
M. Dupuytren. 
In Hoofdstuk 8 bediscussiëren we onze hoofdbevindingen van alle studies, verder 
benoemen we een aantal suggesties voor toekomstig onderzoek. 
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